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Figure S1. Activation of the calcium efflux in HT29 cells induced by representative compounds 
at 10 μM relative to 100% induced by 100 μM of 2f-LIGRLO-NH2 in HT29 cells (data at 100 
μM were not shown). Data represent the average of at least two measurements with SEM.  
	
Figure S2. PAR2 selective antagonists. Concentration dependent curves of 17 (◆), 18 (△), 65 (
▲), versus 3 (◇) based on the inhibition of iCa2+ release in HT29 cells induced by 1 μM 2f-
LIGRLO-NH2. Each data point represents mean ± SEM (n ≥ 3).  	
	
Figure	S3.	Comparison	of	PAR1	and	PAR2	in	HT29	and	PC3	cells.	(a)	Trypsin-	(¡)	versus	thrombin-	 (n)	 induced	 iCa2+	 release	 in	 HT29	 cells,	 indicating	 PAR2	 agonist	 induced	 a	concentration-dependent	response,	while	PAR1	agonist	induced	a	negligible	response	even	at	the	maximum	concentration	of	100	nM.	(b)	PAR1	mRNA	expression	in	HT29	versus	PC3	cells,	 indicating	 PAR1	 expression	 in	 HT29	 cells	 was	 very	 low.	 (c)	 Similar	 level	 of	 PAR2	mRNA	expression	in	HT29	and	PC3	cells.	Each	data	point	represents	mean	±	SEM	(n	≥	3).	
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Figure S4. Mechanism of PAR2 antagonism in iCa2+ function. (a) 65 is a competitive yet  
insurmountable PAR2 antagonist against 2f-LIGRLO-NH2 showing concentration-dependent 
(zero,  l; 0.1 μM, n; 0.3 μM, ▲; 1 μM, ¡; 3 μM, o; 6 μM, △) inhibition of iCa2+ release in 
HT29 cells induced by varying concentrations of PAR2 agonist 2f-LIGRLO-NH2.  (b) Schild 
analysis of 65 against 2f-LIGRLO-NH2 showing competitive mode. Calculated pA2 values for 
65 were 5.9 ± 0.3 against 2f-LIGRLO-NH2 (6.3 ± 0.3 for 3, competitive and surmountable). 
Each data point represents mean ± SEM (n = 3).  
Figure S5. Stability of selective PAR2 ligands in rat plasma (a) and rat liver homogenate (b) at 
37 ºC over 3 h. SLIGRL-NH2 (▽), GB88 (◇), 17 (◆) and 65 (★). Data represent mean ± SEM (n 
= 3). 								
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Table S1. Pharmacokinetic data of new antagonist 65 in comparison with GB88 after oral dose 
(10 mg/kg in olive oil, male Wistar rat)a 
Compound 
3 
(n = 7) 
65 
(n = 4) 
Tmax (min) 167 ± 18 173 ± 31 
Cmax (µM) 1.97± 0.38 1.45 ± 0.39 
AUC6h 
(ng•h/mL) 3420 1964 
a Data represent mean ± SEM (n = 3). 
 
Experimental Section 
All amino acid derivatives were purchased from Novabiochem and used as received. DMF, 
TFA, and diisopropylethylamine (DIEA) were “peptide grade” obtained from Auspep Pty Ltd., 
Australia. Other chemicals were obtained from Sigma-Aldrich and used as received.  LCMS was 
performed using an Agilent 6110 Quadrupole LC/MS (API-ES) equipped with an Agilent 1100 
Series ELS and a single wavelength (UV230 nm) detector with a Phenomenex Luna 5 µm, C18 
250 ´ 4.60 mm column. Five standard conditions were used for all compounds unless otherwise 
indicated at a flow rate of 1 mL/min. Method I: 20% to 100% B linear gradient over 10 min 
followed by a further 10 min at 100% B; Method II: 50% to 100% B linear gradient over 10 min 
followed by a further 10 min at 100% B; Method III: 90% B isocratic for 10 min; Method IV: 
20% to 100% B linear gradient over 15 min followed by a further 10 min at 100% B; Method V: 
5% to 100% B linear gradient over 15 min followed by a further 10 min at 100% B; where 
solvent B was MeCN + 0.1% formic acid and solvent A was H2O + 0.1% formic acid. HPLC 
was performed using an Agilent 1200 Series with a diode-array detector on a Phenomenex Luna 
5 µm, C18 or C8 250 ´ 4.60 mm column. The solvent gradient was the same as LCMS except 
0.1% TFA was used instead of 0.1% formic acid. Preparative-scale reverse-phase HPLC 
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separations were performed on a 15 µm Phenomenex Luna C18 250 ´ 21.2 mm column, using a 
Waters 600 series HPLC. Standard conditions were used for all compounds unless otherwise 
indicated at a flow rate of 20 mL/min: 50% to 100% B linear gradient over 10 min followed by a 
further 10 min at 100% B where solvent B was 90% MeCN, 10% H2O + 0.1% TFA and solvent 
A was H2O + 0.1% TFA. All synthesized compounds were ≥ 95% pure by HPLC. 
Mass spectra were obtained on a triple quadrupole mass spectrometer (PE SCIEX API III) 
using electrospray ionization (ESI-MS) from solutions in 75% MeCN + 25% H2O + 0.1% formic 
acid. Electrospray ionization high-resolution mass spectra (ESI-HRMS) measurements were 
obtained on a Bruker micrOTOF mass spectrometer equipped with an Agilent 1100 Series 
LC/MSD mass detector in positive ion mode by direct infusion in MeCN at 100 μL/h using 
sodium formate clusters as an internal calibrant.  
1H and 13C NMR spectra were recorded on either a Varian Gemini 400 or Bruker Avance 600 
spectrometers at 298 K in the solvents indicated and referenced to residual signals in the 
deuterated solvents (1H at δ 7.26 for CDCl3 and 2.50 for DMSO-d6; 13C at δ 77.16 for CDCl3 and 
39.52 for DMSO-d6). All compounds were di-or tri-peptide like molecules (3 and 6–76) and 
contained generally two rotamers as observed in both 1H and 13C NMR. Further complication of 
NMR was caused by the presence of tertiary amide derived from piperidine ring, which 
displayed asymmetry of each ring methylene unit due to its syn- or anti-orientation relative to 
amide carbonyl. More distinct in 13C than 1H NMR, most of the signals were duplicated with a 
separation of ~0.5–2 ppm. Total assignments of proton and carbon NMR of representative 
compounds were determined using various one- and two-dimensional NMR experiments 
(JMOD, gCOSY, gHSQC, gHMBC). Characteristically, the unsymmetrical Hequatorial and Haxial of 
s-syn piperidine-NCH2 were always separated more apart than s-anti piperidine-NCH2 (Dd ~1.9 
vs ~1.1 ppm) due to the deshielding effect of the amide carbonyl on Hequatorial of s-syn methylene. 
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Accordingly, the corresponding methylene carbon was shielded, i.e.,  Dd ~3.5 ppm between 
carbons of s-anti and s-syn piperidine-NCH2. To distinguish the possibility of rotational isomers 
rather than epimers, NMR at elevated temperatures was investigated and some coalescence was 
observed (Supporting Information Figure S2). The presence of two rotamers rather than epimers 
was further evidenced by solvent-dependent ratio change of two isomers. For example, 
compound 75 showed two rotamers in a ratio of 1:1 in CDCl3 and 3:2 in DMSO-d6.  
General procedure for the synthesis of compounds 3, 12–76. Compounds were synthesized 
in solution phase using Boc-protected amino acids or carboxylic acid, starting from C-terminal 
amine residue. The product was either purified as a final product using reversed-phase 
preparative HPLC or directly used for next step.  If necessary, the Boc protecting group was 
removed and subsequent amide coupling was repeated. Each coupling reactions were monitored 
by ESMS, with most reactions went to completion overnight. Where required, post-coupling 
modification was carried out. Analytical data of representative compounds were listed below and 
all the rest summarized in Supporting Information. 
General procedure for amide coupling. To a solution of the acid (1.2 mmol) in DMF (2 mL) 
was added a solution of HBTU (1.2 mmol) in DMF (2 mL) and DIPEA (1.2 mmol, or 2.4 mmol 
if the amine added as TFA or HCl salts).  The medium was checked using pH paper to make sure 
pH > 8, if necessary, another aliquot of DIPEA was added. The mixture was stirred at rt for 15 
min and added into a solution of the amine (1 mmol) in DMF (1 mL).  The mixture was stirred at 
rt overnight and evaporated to dryness on rotavapor.  The residue was re-dissolved in ethyl 
acetate (6 mL) and washed with sat. aqueous NaHCO3 solution (3 ´ 6 mL).  In parallel synthesis, 
the extraction was facilitated by centrifuging the mixture in a 15 mL Falcon tube at 3000 rpm for 
5 min. The aqueous phase was removed using a Pasteur pipette. The organic phase was dried 
(anhydrous MgSO4, 30 min), filtered using a small cotton ball and a pipette, and evaporated on 
  S8 
rotavapor to give the crude product, which was either purified as final product (yield 60–95%) or 
used directly for next step.  
General procedure for Boc-deprotection.  The substrate (1 mmol) was dissolved in a solution 
of TFA (0.5 mL) in dichloromethane (2 mL).  The mixture was stirred at rt for 2 h and 
evaporated on rotavapor to dryness.  The residue was either purified as final product (yield 60–
99%) or co-evaporated twice with toluene (3 ´ 2 mL), pumped to dryness on high vacuum for 1 
h, and used directly for next round of amide coupling. 
5-isoxazoyl-Cha-Ile-spiro[1H-indene-1,4'-piperidine]  (3). 56% yield in six steps from 6. 1H 
NMR (600 MHz, DMSO-d6) (two rotamers in a ratio of 64:36) δ 0.84–1.00 (m, 8H), 1.05–1.42 
(m, 7H), 1.50-2.00 (m, 11H), 3.04 (td, J = 12.6, 1.8 Hz, 0.64H) and 3.10 (td, J = 12.6, 2.4 Hz, 
0.36H, Hax of s-syn amide piperidine NCH2), 3.48 (t, J = 12.6 Hz, 1H, Hax of s-anti amide 
piperidine NCH2), 4.18 (d, J = 13.8 Hz, 0.36H) and 4.21 (d, J =13.8 Hz, 0.64H, Heq of s-anti 
amide piperidine NCH2), 4.44 (d, J = 13.8 Hz, 0.36 H) and 4.52 (d, J = 13.8 Hz, 0.64H, Heq of s-
syn amide piperidine NCH2), 4.57–4.65 (m, 1H, Cha-a-CH), 4.68–4.73 (m, 1H, Ile-a-CH), 6.82 
(d, J = 5.6 Hz, 1H, indene-CH), 7.07–7.38 (m, 6H), 8.16 (d, J = 9.0 Hz, 0.36H) and 8.31 (d, J = 
9.0 Hz, 0.64H, Ile-NH), 8.77 (d, J = 1.8 Hz, 1H, isoxazole-3-CH), 8.91 (d, J = 8.4 Hz, 0.36H) 
and 9.00 (d, J = 8.4 Hz, 0.64H, Cha-NH); 13C NMR (150 MHz, DMSO-d6): 11.1/11.2 (CH3, Ile-
d-CH3), 15.6/15.9 (CH3, Ile-g-CH3), 24.0 (CH2, Ile-g-CH2), 25.7(0)/25.7(3) (CH2, Cha-CH2), 25.9 
(CH2, Cha-CH2), 26.1 (CH2, Cha-CH2), 31.8(0)/31.8(1) (CH2, Cha-CH2), 33.1(6)/33.1(8) (CH2, 
Cha-CH2), 33.2(5)/33.3(1) (CH2, s-syn amide piperidine N CH2CH2), 33.7(5)/33.7(9) (CH, Cha-
g-CH), 33.9/34.1 (CH2, s-anti amide piperidine N CH2CH2), 36.3/36.6 (CH, Ile-b-CH), 38.9/39.1 
(CH2, Cha-b-CH2), 40.3/40.5 (CH2, s-syn amide piperidine NCH2), 44.0/44.3 (CH2, s-anti amide 
piperidine NCH2), 51.1 (CH, Cha-a-CH), 52.0/52.1(8) (C, spiro-C), 52.1(7)/52.3 (CH, Ile-a-
CH), 106.2(7)/106.3(2) (CH, isoxazole-4-CH), 121.4(0)/121.4(3) (CH), 121.4(7)/121.6(4) (CH), 
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125.2/125.4 (CH), 127.0(0)/127.0(4) (CH), 129.8(9)/129.9(2) (CH, indene-3-CH), 
141.3(7)/141.4(7) (CH, indene-2-CH), 142.5(1)/142.5(7) (C), 151.2/151.3 (C), 151.8 (CH, 
isoxazole-3-CH), 155.4(7)/155.4(9) (C), 162.5 (C), 169.5/169.6 (C, Ile-CO), 171.3(0)/171.3(2) 
(C, Cha-CO). HRMS: calcd for C32H43N4O4+ [MH]+: 547.3279, found: 547.3291. LCMS tR = 16.2 
min. HPLC tR = 15.5 min (Method IV). 
General procedure for N-methylation.  A solution of the amine (1 mmol) in anhydrous DCM 
(2 mL) was added anhydrous triethylamine (2.1 mmol) and 2-nitrobenzenesulfonyl chloride 
(1.05 mmol). The mixture was stirred at rt for 2 h, diluted with DCM (4 mL) and washed with 
water (4 mL).  The DCM phase was dried (MgSO4), filtered and evaporated on rotovap to 
dryness. The residue (pale-yellow foam) was dried under P2O5 under high vacuum for 1 h.  The 
crude was dissolved in anhydrous DMF (2 mL), treated with DBU (2 mmol) and cooled in an 
ice-water bath while dimethyl sulfate (3 mmol) was added dropwise. After stirred at 0 ºC for 15 
min, the mixture was treated with acetic acid (1.1 mmol) and evaporated under high vacuum.  
The residue was taken up in ethyl acetate (5 mL) and washed with sat. aqueous solution of 
NaHCO3 (3 ´ 4 mL) and water (4 mL).  The organic phase was dried (MgSO4), filtered and 
evaporated.  The crude was dissolved in DCM (4 mL) and treated with DBU (1.5 mmol) and 2-
thioethanol (3 mmol).  The mixture was stirred at rt for 30 min and treated with sat. aqueous 
solution of NaHCO3 (4 mL).  The mixture was stirred vigorously at rt for 10 min and centrifuged 
(250 rpm for 5 min).  The organic phase was removed using a Pasteur pipette, dried (MgSO4), 
filtered and evaporated on rotovap.  The crude N-methylated amine was either purified by 
preparative HPLC, or co-evaporated with toluene (2 ´ 3 mL) and used for next coupling.  
(N-Me)Cha-Ile-spiro[1H-indene-1,4'-piperidine] as TFA salt. 1H NMR (400 MHz, CDCl3) 
(two rotamers in a ratio of 1:1) δ 0.87–1.03 (m, 8H), 1.10–2.11 (m, 18H), 2.72 (s)/2.74 (s, 3H, 
NCH3), 3.03–3.11 (m, 1H, Hax of s-syn amide piperidine-NCH2), 3.42–3.51 (m, 1H, Hax of s-anti 
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amide piperidine-NCH2), 3.94–4.01 (m, 1H, Cha-a-CH), 4.15–4.20 (m, 1H, Heq of s-anti amide 
piperidine-NCH2), 4.61–4.68 (m, 1H, Heq of s-syn amide piperidine-NCH2), 4.91–4.98 (m, 1H, 
Ile-a-CH), 6.78–6.85 (m, 2H, 2´ indene-CH), 7.16–7.35 (m, 4H), 7.88–7.94 (m, 1H, NH); 13C 
NMR (100 MHz, CDCl3) δ 11.0/11.2 (Ile-d-CH3), 15.6/16.0 (Ile-g-CH3), 24.1/24.2 (Ile-g-CH2), 
25.7(9)/25.8(5) (CH2),  25.9(4) (CH2),  26.0(1) (CH2),  31.6 (NCH3), 32.6/32.7 (CH2), 33.3(7) 
(CH2), 33.4(3)/33.4(8), 33.7/33.8 (CH2, s-syn amide piperidine NCH2CH2), 34.2/34.3(CH2, s-anti 
amide piperidine NCH2CH2), 37.3/37.4 (Ile-b-CH), 37.9 (Cha-g-CH), 41.3/41.4 (s-syn amide 
piperidine NCH2), 44.9/45.2 (s-anti amide piperidine NCH2), 51.8/51.9 (spiro-C), 53.6 (Ile-a-
CH), 60.6 (Cha-a-CH), 116.3 (q, 1JF–C = 290 Hz, CF3COO–), 121.4/121.5 (CH), 
121.6(5)/121.7(2) (CH), 125.5/125.6 (CH), 127.3(0)/127.3(3) (CH), 130.9(7)/131.0(1) (indene-
CH), 139.3/139.5 (indene-CH), 142.6/142.7 (C), 150.7 (C), 162.0 (q, 2JF–C = 36.7 Hz, CF3COO–), 
167.7(7)/167.8(0) (C), 169.7/169.8 (C). HRMS: calc. for C29H44N3O2+ [MH]+: 466.3428, found: 
466.3424. HPLC tR = 9.3 min (Method I). 
5-isoxazoyl-Cha-(N-Me)Ile-spiro[1H-indene-1,4'-piperidine]. 1H NMR (400 MHz, DMSO-d6) 
(two rotamers in a ratio of 70:30) δ 0.79–1.96 (m, 25H), 2.06–2.14 (m, 1H, Ile-b-CH), 2.97 (s, 
minor) and 3.06 (s, major, 3H, N-Me), 2.99–3.17 (m, 1H, s-syn amide piperidine NCH2), 3.30–
3.46 (m, 1H, s-anti amide piperidine NCH2), 4.11 (d, J = 13.6 Hz, minor) and 4.18 (d, J = 13.6 
Hz, manor, 1H, s-anti amide piperidine NCH2CH2), 4.43 (d, J = 13.6 Hz, minor) and 4.56 (d, J = 
13.6 Hz, major, 1H, s-syn amide piperidine NCH2), 4.87–4.97 (m, 1H, Cha-a-CH), 5.07–5.13 
(m, 1H, Ile-a-CH), 6.84 (d, J = 5.6 Hz, major) and 7.07 (d, J = 5.6 Hz, minor, 1H, indene-CH), 
7.10–7.40 (m, 6H), 8.73 (d, J = 2.0 Hz, major) and 8.74 (d, J = 2.0 Hz, minor, 1H, isoxazole-
CH), 9.13 (d, J = 9.0 Hz, minor) and 9.15 (d, J = 8.5 Hz, major, 1H, Cha-NH). 13C NMR (100 
MHz, DMSO-d6): major isomer, 10.8 (Ile-d-CH3), 15.7 (Ile-g-CH3), 23.5 (Ile-g-CH2), 25.5 (Cha-
CH2), 25.7 (Cha-CH2), 26.0 (Cha-CH2), 29.7 (NCH3), 31.2 (Cha-CH2), 32.2 (Ile-b-CH), 33.2 
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(CH2), 33.3 (CH2), 33.6 (CH2), 34.8 (CH, Ile-b-CH), 37.8 (CH2, Cha-b-CH2), 40.4 (s-syn amide 
piperidine NCH2), 43.6 (s-anti amide piperidine NCH2), 47.4 (Cha-a-CH), 52.1 (spiro-C), 55.8 
(Ile-a-CH), 106.1 (isoxazole-4-CH), 121.4 (CH), 121.5 (CH), 125.0 (CH), 127.0(4) (CH), 129.9 
(indene-3-CH), 141.2 (indene-2-CH), 142.5 (C), 151.1 (C), 151.7 (isoxazole-3-CH), 155.6 (C), 
162.1 (C), 167.3 (C), 171.5 (C); minor isomer (only those not overlapped), 10.9 (Ile-d-CH3), 
15.9 (Ile-g-CH3), 25.6 (Cha-CH2), 25.8 (Cha-CH2), 29.8 (NCH3), 31.5 (Cha-CH2), 32.4 (Ile-b-
CH), 33.7 (CH2), 33.9 (CH2), 37.7 (CH2, Cha-b-CH2), 43.4 (s-anti amide piperidine NCH2), 47.5 
(Cha-a-CH), 52.0 (spiro-C), 55.9 (Ile-a-CH), 121.3 (CH), 121.8 (CH), 125.3 (CH), 127.0(0) 
(CH), 141.5 (indene-2-CH), 155.5 (C), 167.7 (C), 171.7 (C). HRMS: calc. for C33H45N4O4+ 
[MH]+: 561.3435, found: 561.3435. HPLC tR = 12.5 min (Method I). 
5-isoxazoyl-(N-Me)Cha-Ile-spiro[1H-indene-1,4'-piperidine]. 1H NMR (DMSO-d6) (two 
rotamers in a ratio of 58:42) δ 0.82–2.05 (m, 26H), 2.96 (s, minor) and 3.07 (s, major, 3H, N-
Me), 3.00–3.10 (m, 1H), 3.43–3.55 (m, 1H), 4.13–4.22 (m, 1H), 4.44–4.52 (m, 1H), 4.63–4.69 
(m, 1H, Ile-a-CH), 5.11–5.19 (m, 1H, Cha-a-CH), 6.83–7.36 (m, 7H), 8.22 (d, J = 8.5 Hz, 
minor) and 8.35 (d, J = 8.8 Hz, major, 1H, Ile-NH), 8.76–8.78 (m, 1H, isoxazole-CH). HRMS: 
calc. for C33H45N4O4+ [MH]+: 561.3435, found: 561.3435. HPLC tR = 12.2 min (Method I). 
(N,N,N-trimethyl)Cha-Ile-spiro[1H-indene-1,4'-piperidine] (7) as trifluoroacetate salt. In a 
microwave vial was loaded a solution of the H2N-Cha-Ile-spiro[1H-indene-1,4'-piperidine] (33 
mg, 0.0731 mmol) in acetone (0.4 mL), methyl iodide (27 µL, 0.439 mmol, 6 eq) and powdered 
Na2CO3 (23 mg, 0.219 mmol, 3 eq).  The vial was sealed and loaded into Biotage Initiator 
microwave reaction system with settings at temperature = 120 ºC and reaction time = 20 min.  
After cooling to room temperature, the mixture was filtered and the filtrate evaporated on 
rotavap. The residue was dissolved in MeCN-H2O (1:1, 4 mL) and purified by preparative 
rpHPLC. The product fractions were identified by ESMS (m/z 494, ammonium cation) and pure 
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fractions (confirmed by analytical rpHPLC) were pooled and lyophilized to give a white 
amorphous powder (21.3 mg, 48% yield).  1H NMR (400 MHz, CDCl3) (two rotamers in a ratio 
of 1:1) δ 0.84–1.02 (m, 8H), 1.05–1.76 (m, 13H), 1.87–2.17 (m, 5H), 3.01–3.12 (m, 1H), 3.29 
(s) and 3.30 (s, 9H, 3 ´ Me), 3.44–3.55 (m, 1H), 4.19–4.25 (m, 1H), 4.64–4.71 (m, 2H), 4.79–
4.87 (m, 1H), 6.81–6.88 (m, 2H), 7.17–7.36 (m, 4H), 9.20–9.24 (m, 1H); 13C NMR (100 MHz, 
CDCl3) δ 10.8/11.0 (Ile-d-CH3), 15.6/16.1 (Ile-g-CH3), 24.8/24.9 (Ile-g-CH2), 25.6(7)/25.7(3), 
26.2, 26.4/26.5, 32.1/32.2, 33.5/33.6, 34.2/34.3, 34.5, 34.6/34.7, 36.4/36.6, 41.3/41.4 (s-syn 
amide piperidine NCH2), 45.1/45.5 (s-anti amide piperidine NCH2), 52.1/52.2 (spiro-C), 52.5 
(+NMe3), 53.8 (Ile-a-CH),  72.3/72.4 (Cha-a-CH), 116.2 (q, 1JF–C = 286 Hz, CF3COO–), 
121.6/121.7 (CH), 121.9 (CH), 125.6/125.7 (CH), 127.4/127.5 (CH), 131.1 (indene-CH), 
139.8/139.9 (indene-CH), 142.9 (C), 150.9(8)/151.0(7) (C), 161.1 (q, 2JF–C = 37.1 Hz, CF3COO–), 
166.4/166.5 (C), 169.5/169.7 (C). HRMS: calcd for C31H48N3O2+ [MH]+: 494.3741, found: 
494.3741. HPLC tR = 10.2 min (Method V). 
Carbamimidoyl-Cha-Ile-spiro[1H-indene-1,4'-piperidine] (8). In a 2 mL HPLC glass vial was 
loaded the H2N-Cha-Ile-spiro[1H-indene-1,4'-piperidine] (46 mg, 0.102 mmol), 1H-pyrazole-1-
carboxamidine HCl salt (15 mg, 0.102 mmol, 1 eq), DMF (204 µL) and DIPEA (18 µL, 0.102 
mmol, 1 eq).  The suspension was stirred at room temperature for 1 h. DCM (102 µL) was added 
to make thick precipitate turn to homogenous solution. After stirred at room temperature 
overnight, the mixture was transferred into a RBF and evaporated on rotavap to dryness.  The 
crude was purified by preparative rpHPLC and the product fractions were pooled (ESMS: m/z 
494, MH+) and lyophilized to give the product as TFA salt (white amorphous solid, 19% yield). 
1H NMR (400 MHz, CDCl3) (two rotamers in a ratio of 1:1) δ 0.87–1.02 (m, 8H), 1.11–1.28 (m, 
4H), 1.37–1.75 (m, 11H), 1.89–2.18 (m, 3H), 3.04–3.12 (m, 1H), 3.44–3.54 (m, 1H), 4.13–4.21 
(m, 2H), 4.53–4.61 (m, 1H), 4.66–4.73 (m, 1H), 6.79–6.83 (m, 2H), 7.12–7.36 (m, 7H), 8.08–
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8.14 (m, 2H). HRMS: calc. for C29H44N5O2+ [MH]+: 494.3490, found: 494.3489. HPLC tR = 10.1 
min (Method V). 
Carbamoyl-Cha-Ile-spiro[1H-indene-1,4'-piperidine] (9). In a 2 mL HPLC glass vial was 
loaded the H2N-Cha-Ile-spiro[1H-indene-1,4'-piperidine] (20 mg, 0.0443 mmol), acetic acid 
(7.6 µL, 0.133 mmol, 3 eq), water (0.48 mL) and MeCN (0.48 mL). The mixture was sonicated 
to give a homogenous solution. A solution of sodium cyanate (8.6 mg, 0.133 mmol, 3 eq) in 
water (0.4 mL) was added to the above reaction mixture dropwise over a period of 4 h. Note: at 
2 h after addition of 0.2 mL of the sodium cyanate solution, rapid precipitation was observed 
and thus extra MeCN (0.4 mL) was added to make the reaction mixture homogenous.  After 
stirred at room temperature overnight. ESMS indicated the complete conversion (m/z 495 MH+ 
and 517 MNa+ exclusively).  The reaction mixture was purified by preparative rpHPLC and the 
desired product fractions were pooled and lyophilized to give a white amorphous powder (9.11 
mg, 42% yield). 1H NMR (400 MHz, CDCl3) (two rotamers in a ratio of 1:1) δ 0.88–1.03 (m, 
8H), 1.10–1.30 (m, 4H), 1.32–2.14 (m, 14H), 3.06–3.12 (m, 1 H), 3.44–3.54 (m, 1H), 4.16 (m, 
1H), 4.31 (br s, 1H), 4.61–4.69 (m, 1H), 4.89–4.91 (m, 1H), 6.01 (br s, 1H), 6.82–6.87 (m, 2H), 
7.14–7.38 (m, 6H). HRMS: calc. for C29H43N4O3+ [MH]+ 495.3330, found 495.3340; HPLC tR = 
9.4 min (Method II). 
(2-Hydroxyethylcarbamoyl)-Cha-Ile-spiro[1H-indene-1,4'-piperidine] (10). In a 2 mL HPLC 
glass vial was loaded triphosgene (5.3 mg, 0.0177 mmol, 0.4 eq) and anhydrous DCM (100 µL). 
A solution of the H2N-Cha-Ile-spiro[1H-indene-1,4'-piperidine] (20 mg, 0.0443 mmol, 1 eq) in 
DIPEA (17 µL, 0.0975 mmol, 2.2 eq) and anhydrous DCM (100 µL) was added dropwise. After 
5 min, a solution of ethanolamine (2.9 µL, 0.0487 mmol, 1.1 eq) in anhydrous DCM (100 µL) 
was added in one portion. The mixture was stirred at room temperature overnight and transferred 
into a RBF.  The mixture was evaporated on rotavap and the residue was treated with MeCN (5 
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mL). The mixture was heated to reflux, cooled and filtered. The filtrate was purified by 
preparative rpHPLC and the desired product fractions were pooled and lyophilized to give a 
white amorphous powder (7.05 mg, 30% yield). 1H NMR (400 MHz, CDCl3) (two rotamers in a 
ratio of 1:1) δ 0.89–1.06 (m, 8H), 1.10–1.32 (m, 4H), 1.34–1.60 (m, 5H), 1.62–1.88 (m, 7H), 
1.90–2.40 (m, 4H), 3.04–3.14 (m, 1 H), 3.30–3.60 (m, 2H), 3.75 (br s, 2H), 4.12–4.30 (m, 2H), 
4.58–4.70 (m, 1H), 4.84–4.94 (m, 1H), 5.66 (br s, 1 H), 6.82–6.87 (m, 2H), 7.14–7.38 (m, 5H). 
HRMS: calc. for C31H47N4O4+ [MH]+ 539.3592, found 539.3600; HPLC tR = 9.1 min (Method II). 
Benzylcarbamoyl-Cha-Ile-spiro[1H-indene-1,4'-piperidine] (11). In a 2 mL HPLC glass vial 
was loaded the H2N-Cha-Ile-spiro[1H-indene-1,4'-piperidine] (20 mg, 0.0443 mmol, 1 eq), 
DCM (150 µL), and benzyl isocyanate (5.4 µL, 0.0443 mmol, 1 eq). The mixture was stirred at rt 
overnight and transferred into a RBF.  The mixture was evaporated on rotavap and the residue 
was dissolved in MeCN (5 mL) and purified by preparative rpHPLC and the desired product 
fractions were pooled and lyophilized to give a white amorphous powder (8.50 mg, 33% yield).  
1H NMR (400 MHz, CDCl3) (two rotamers in a ratio of 1:1) δ 0.86–1.02 (m, 8H), 1.06–2.20 (m, 
18H), 2.98–3.08 (m, 1H), 3.39–3.48 (m, 1H), 4.07–4.15 (m, 1H), 4.30–4.46 (m, 3H), 4.56–4.67 
(m, 1H), 4.84–4.91 (m, 1H), 5.25 (br s, 1 H), 6.80–7.37 (m, 12H). HRMS: calc. for C36H49N4O3+ 
[MH]+ 585.3799, found 585.3807; HPLC tR = 12.3 min (Method II). 
5-Isoxazoyl-Cha-Ile-(4-phenylpiperidine) (65). 46% yield in five steps. 1H NMR (600 MHz, 
DMSO-d6) (two rotamers in a ratio of 60:40) δ 0.78–0.95 (m, 8H), 0.99–1.21 (m, 4H), 1.25–1.44 
(m, 2H), 1.44–1.90 (m, 12H), 2.59–2.68 (m, 1H, Hax of s-syn amide piperidine NCH2), 2.75–2.83 
(m, 1H, piperidine-CHPh), 3.09 (app t, J = 12.0 Hz, minor) and 3.14 (app t, J = 12.0 Hz, major, 
1H, Hax of s-anti amide piperidine NCH2), 4.19 (d, 1H, J = 13.2 Hz, Heq of s-anti amide 
piperidine NCH2), 4.53–4.59 (m, 2H, Cha-a-CH and Heq of s-syn amide piperidine NCH2), 4.60–
4.65 (m, 1H, Ile-a-CH), 7.14–7.41 (m, 6H), 8.14 (d, J = 8.4 Hz, minor) and 8.28 (d, J = 9.0 Hz, 
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major, 1H, Ile-NH), 8.74 (d, J = 1.8 Hz, major) and 8.75 (d, J = 1.8 Hz, minor, 1H, isoxazole-
CH), 8.94 (d, J = 7.2 Hz, minor) and 8.95 (d, J = 7.8 Hz, major, 1H, Cha-NH); 13C NMR (150 
MHz, CDCl3): 11.5/11.7 (CH3, Ile-d-CH3), 16.0/16.3 (CH3, Ile-g-CH3), 24.3/24.4 (CH2, Ile-g-
CH2), 26.0(8)/26.1(7) (CH2), 26.2(5)/26.3(0) (CH2), 26.5 (CH2), 32.1(8)/32.2(0) (CH2), 
33.3(8)/33.4(4) (CH2), 33.6(7)/33.7(0) (CH2), 34.1 (CH, Cha-g-CH), 34.2 (CH2), 36.6/36.9 (CH, 
Ile-b-CH), 39.3/39.5 (CH2, Cha-b-CH2), 42.0/42.2 (CH, piperidine CHPh), 42.6/42.7 (CH2, s-syn 
amide piperidine NCH2), 46.1/46.3 (CH2, s-anti amide piperidine NCH2), 51.3/51.4 (CH, Cha-a-
CH), 52.5/52.6 (CH, Ile-a-CH), 106.6/106.7 (CH, isoxazole-4-CH), 126.7 (CH), 
127.0(9)/127.1(3) (CH), 128.9/129.0 (CH), 145.9/146.0 (C), 152.2 (CH, isoxazole-3-CH), 155.8 
(C), 162.8 (C), 169.6/169.7 (C, Ile-CO), 171.6/171.7 (C, Cha-CO). HRMS: calc. for C30H43N4O4+ 
[MH]+ 523.3279, found 523.3280. HPLC tR = 10.0 min (Method II). 
Scheme S1. Synthesis of 44. (a) O(CH2CH2Cl)2 (1 eq), 2M NaOH (3 eq), 1,4-dioxane, 
microwave (Biotage Initiator), 100 ºC, 2 h;  (b) HBTU (1.1 eq), DIPEA (1.1 eq), DMF, rt, 18 h; 
(c) 20% TFA in DCM, rt, 2 h; (d) isoxazole-5-carboxylic acid (1.2 eq), HBTU (1.2 eq), DIPEA 
(1.2 eq), DMF, rt, 18 h. 
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Scheme S2. Synthesis of 50. (a) carboxylic acid (i.e., Boc-Thr-OH, Boc-Cha-OH or isoxazole-5-
carboxylic acid, 1.2 eq), HBTU (1.2 eq), DIPEA (1.2 eq), DMF, rt, 18 h; (b) i) LiOtBu (1.05 eq), 
DMF, rt, 1 h; ii) MeI (1.1 eq), rt, 18 h; (c) 20% TFA in DCM, rt, 2 h. 
 
 
Scheme S3. Synthesis of 54. mCPBA (2 eq), DCM–sat. NaHCO3 (1:1, v/v). rt, 3 days. 
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Figure S5. 1H NMR of representative compound 65 at elevated temperature in DMSO-d6. At 
298K, isoxazole proton Ha split into 2 sets of doublets (8.75 ppm), amide NHb into 2 sets of 
doublets (8.94 ppm, appeared as triplet due to overlapping signals) and  Ile-a-CH (He) was 
multiplet at 4.64 ppm. They all simplified at 318K with Ha appeared as one broad singlet, Hb as 
a sharp doublet (coupling with Cha-a-CH, Hc) and He as a triplet (coupling with Ile-NH, Hd and 
Ile-b-CH). However, at this temperature, the asymmetry caused by amide group derived from 
piperidine ring was still present with two distinguished methylene pairs (Haxial and Hequatorial) of s-
syn and s-anti NCH2 of piperidine ring clearly observable.   
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ID R1 Analytical data 
12  
tR = 13.0 min (Method II); HRMS: calc. for C32H43N4O4+ [MH]+ 
547.3279, found 547.3279; 1H NMR (600 MHz, DMSO-d6) (two 
rotamers in a ratio of 62:38) δ 0.82-0.97 (m, 8H), 1.06–1.36 (m, 7H), 
1.47–1.97 (m, 11H), 3.00–3.09 (m, 1H), 3.44–3.48 (m, 1H), 4.15–4.19 
(m, 1H), 4.41 (br d, J = 13.5 Hz, 0.38H) and 4.50 (br d, J = 13.4 Hz, 
0.62H), 4.56–4.63 (m, 1H), 4.68–4.72 (m, 1H), 6.82 (d, J = 5.6 Hz, 
1H), 6.93 (d, J = 1.60 Hz, 1H), 7.05–7.35 (m, 5H), 8.11 (d, J = 8.7 Hz, 
0.38H) and 8.24 (d, J = 9.04 Hz, 0.62H), 8.74 (d, J = 8.5 Hz, 0.38H) 
and 8.78 (d, J = 8.4 Hz, 0.62H), 9.10–9.11 (m, 1H). 
13  
tR = 10.9 min (Method II); HRMS: calc. for C33H44N3O4+ [MH]+ 
546.3326, found 546.3330; 1H NMR (400 MHz, CDCl3) (two rotamers 
in a ratio of 1:1) δ 0.85–0.94 (m, 4H), 0.97–1.0 (m, 2H), 1.05–1.28 (m, 
4H), 1.37–1.58 (m, 4H), 1.62–1.74 (m, 4H), 1.75–1.85 (m, 6H), 1.91–
2.14 (m, 2H), 3.00–3.02 (m, 1H), 3.41–3.52 (m, 1H), 4.12–4.18 (m, 
1H), 4.61–4.75 (m, 2H), 4.88–4.95 (m, 1H), 6.51 (dd, 1H, J = 2.0, 3.4 
Hz), 6.77–6.87 (m, 4H), 7.14 (d, 1H, J = 3.2 Hz), 7.19–7.36 (m, 4H), 
7.46 (br s, 1H); 13C NMR (100 MHz, CDCl3): 11.6/11.8 (CH3, Ile-d-
CH3), 16.1/16.4 (CH3, Ile-g-CH3), 24.3, 26.2(7)/26.3(0), 
26.4(0)/26.4(5), 26.6, 32.8(6)/32.9(1), 33.5/33.6, 34.0, 34.2(8)/34.3(5), 
34.3(9)/34.5, 38.4, 40.4/40.5, 41.3 (br, s-syn amide piperidine NCH2), 
45.0/45.4, 51.1 (br, s-anti amide piperidine NCH2), 52.1/52.3 (spiro-C), 
53.1(6)/53.2(2)/53.2(9) (2 ´ a-CH), 112.3(8)/112.4(4), 115.0, 
121.7/121.8, 121.9/122.0, 125.7/125.8, 127.4/127.5, 131.0(7)/131.1(1), 
139.8/140.0, 142.8/143.0, 144.3(8)/144.4(2), 147.7, 151.1/151.2, 158.3, 
170.3, 172.1. 
14 
 
tR = 6.6 min (Method II); HRMS: calc. for C32H44N5O3+ [MH]+ 
546.3439, found 546.3437; 1H NMR (400 MHz, CDCl3) (two rotamers 
in a ratio of 1:1) δ 0.78–0.99 (m, 8H), 1.10–1.25 (m, 4H), 1.38–1.50 
(m, 4H), 1.60–1.62 (m, 2H), 1.70–1.89 (m, 6H), 1.93–2.11 (m, 2H), 
3.00–3.10 (m, 1H), 3.46 (t, 1H, J = 12.8 Hz), 4.25 (d, 1H, J = 12.4 Hz), 
4.57–4.66 (m, 1H), 4.70–4.90 (m, 1H), 5.02 (q, 1H, J = 8.0 Hz), 6.77–
6.82 (m, 2H), 7.19–7.26 (m, 5H), 7.31–7.35 (m, 1H), 7.90–8.00 (br s, 
1H), 8.40–8.48 (br s, 1H), 8.49–8.62 (br s, 1H).  
15  
tR = 9.7 min (Method II); HRMS: calc. for C32H43N4O4+ [MH]+ 
547.3279, found 547.3278; 1H NMR (600MHz, CDCl3) (two rotamers 
in a ratio of 1:1) δ 0.86–0.97 (m, 5H), 1.01 (d, 2H, J = 6.8 Hz), 1.1–
1.28 (m, 4H), 1.28–1.6 (m, 4H), 1.61–1.78 (m, 5H), 1.78–1.90 (m, 2H), 
1.91–2.07 (m, 2H), 2.09–2.16 (m, 1H), 3.05–3.16 (m, 1H), 3.44–3.56 
(m, 2H), 4.14–4.22 (m, 1H), 4.61–4.76 (m, 2H), 4.93 (q, 1H, J = 7.2 
N
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Hz), 6.83–6.92 (m, 2H), 7.09 (dd, 1H, J = 8.8, 18 Hz), 7.18–7.36 (m, 
5H), 7.76 (s, 1H), 7.95 (s, 1H).  
16 
 
tR = 8.9 min (Method II); HRMS: calc. for C31H43N6O3+ [MH]+ 
547.3391, found 547.3391; 1H NMR (400 MHz, CDCl3) (two rotamers 
in a ratio of 1:1) δ 0.80–1.01 (m, 9H), 1.10–1.26 (m, 5H), 1.40–1.58 
(m, 5H), 1.66–1.88 (m, 5H), 1.98–2.18 (m, 2H), 3.16 (t, 1H, J = 12.4 
Hz), 3.56 (q, 1H, J = 13.6 Hz), 4.78–4.85 (m, 1H), 5.10–5.20 (m, 1H), 
5.21–5.40 (m, 1H), 6.84–6.88 (m, 2H), 7.21–7.37 (m, 4H), 8.02–8.21 
(m, 2H), 8.80–8.85 (m, 1H).  
17  
tR = 15.0 min (Method IV); HRMS: calc. for C32H44N5O4+ [MH]+ 
562.3388, found 562.3388; 1H NMR (400 MHz, CDCl3) (two rotamers 
in a ratio of 1:1) δ 0.84–1.04 (m, 8H), 1.08–2.24 (m, 18H), 3.05–3.16 
(m, 1H), 3.44–3.59 (m, 1H), 4.19–4.26 (m, 1H), 4.60–4.77 (m, 2H), 
4.93–5.01 (m, 1H), 6.47 (s, 1H), 6.82–6.87 (m, 2H), 7.18–7.49 (m, 
6H); 13C NMR (100 MHz, DMSO-d6) δ 11.2/11.4 (Ile-d-CH3), 
15.6/16.0 (Ile-g-CH3), 24.2 (Ile-g-CH2), 26.0, 26.1(0)/26.1(3), 26.2, 
32.4(0)/32.4(2), 33.2/33.4, 33.5(9)/33.6(2), 34.1, 37.8(8)/37.9(4), 
40.1/40.2, 41.4/41.5, 45.1/45.6, 51.4/51.5, 51.8/51.9, 53.1, 99.9 
(isoxazole-4-CH), 121.4/121.6, 121.8, 125.5/125.7, 127.3/127.4, 
131.0/131.1 (indene-3-CH), 139.3/139.7 (indene-2-CH), 142.5/142.8, 
150.7/150.8, 155.8, 162.0/163.6, 170.6(5)/170.6(8), 171.8/171.9. 
18  
tR = 6.2 min (Method II); HRMS: calc. for C33H46N5O4+ [MH]+ 
576.3544, found 576.3544; 1H NMR (600 MHz, DMSO-d6) (two 
rotamers in a ratio of 2:1) δ 0.80–0.97 (m, 8H), 1.04–1.21 (m, 5H), 
1.22–1.38 (m, 2H), 1.47–1.62 (m, 3H), 1.62–1.77 (m, 5H), 1.77–1.99 
(m, 3H), 2.99–3.10 (m, 1H), 3.46 (t, 1H, J = 13 Hz), 4.17 (t, 1H, J = 14 
Hz), 4.24–4.30 (m, 2H), 4.43 (d, J = 13 Hz, minor) and 4.50 (d, J = 13 
Hz, major, 1H), 4.54–4.62 (m, 1H), 4.64–4.70 (m, 1H), 6.84 (d, J = 5.6 
Hz, major) and 7.06 (d, J = 5.6 Hz, minor, 1H), 7.13–7.20 (m, 1H), 
7.21–7.28 (m, 2H), 7.32–7.36 (m, 1H), 8.16 (d, J = 8.8 Hz, minor) and 
8.31 (d, J = 8.8 Hz, major, 1H), 8.50 (br s, 2H), 9.12 (d, J = 8.0 Hz, 
minor) and 9.14 (d, J = 8.0 Hz, major, 1H) 
19  
tR = 9.6 min (Method I) or 13.7 (Method IV); HRMS: calc. for 
C32H45N6O3+ [MH]+ 561.3548, found 561.3548; 1H NMR (400 MHz, 
CDCl3) (two rotamers in a ratio of 1:1) δ 0.80–1.04 (m, 8H), 1.06–2.20 
(m, 18H), 3.04–3.16 (m, 1H), 3.46–3.56 (m, 1H), 4.17–4.24 (m, 1H), 
4.76–4.81 (m, 2H), 5.01–5.08 (m, 1H), 6.04 (br s, 1H), 6.80–6.85 (m, 
2H), 7.18–7.35 (m, 5H), 7.78 (br s, 1H), 8.40 (br s, 1H). 
20  
tR = 12.8 min (Method II); HRMS: calc. for C32H43N4O3S+ [MH]+ 
563.3051 found 563.3049; 1H NMR (600 MHz, DMSO-d6) (two 
rotamers in a ratio of 2:1) δ 0.78–0.97 (m, 8H), 1.04–1.36 (m, 7H), 
1.44–1.73 (m, 7H), 1.73–1.98 (m, 4H), 2.97–3.11 (m, 1H), 3.46 (t, J = 
13.2 Hz, 1H), 4.14–4.23 (m, 1H), 4.41 (d, J = 13 Hz, minor) and 4.49 
(d, J = 13 Hz, major, 1H), 4.60–4.74 (m, 2H), 6.83 (d, J = 5.7 Hz, 
major) and 7.04 (d, J = 5.7 Hz, minor, 1H), 7.08–7.27 (m, 3H), 7.31–
7.38 (m, 1H), 8.25 (d, J = 8.8 Hz, 0.4H), 8.33–8.45 (m, 2.6H), 9.22 (d, 
J = 2.0 Hz, minor) and 9.23 (d, J = 2.0 Hz, major, 1H). 
21 
 
tR = 13.2 min (Method II); HRMS: calc. for C32H43N4O3S+ [MH]+ 
563.3051, found 563.3049; 1H NMR (600 MHz, DMSO-d6) (two 
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rotamers in a ratio of 2:1) δ 0.79–1.00 (m, 8H), 1.03–1.45 (m, 7H), 
1.46–1.77 (m, 8H), 1.77–2.03 (m, 3H), 2.97–3.12 (m, 1H), 3.46 (t, J = 
13.3 Hz, 1H), 4.12–4.23 (m, 1H), 4.41 (d, J = 13.3 Hz, minor) and 4.51 
(d, J = 13.3 Hz, major, 1H), 4.53–4.61 (m, 1H), 4.64–4.70 (m, 1H), 
6.84 (d, J = 5.6 Hz, major) and 7.05 (d, J = 5.6 Hz, minor, 1H), 7.12–
7.31 (m, 3H), 7.31–7.37 (m, 1H), 8.07 (d, J = 9.0 Hz, minor) and 8.22 
(d, J = 9.0 Hz, major, 1H), 8.56–8.62 (m, 1H), 8.68–8.76 (m, 1H), 9.23 
(br s, 1H). 
22 
 
tR = 15.0 min (Method IV); HRMS: calc. for C32H44N5O3S+ [MH]+ 
578.3159, found 578.3161; 1H NMR (600 MHz, DMSO-d6) (two 
rotamers in a ratio of 2:1) δ 0.79–0.97 (m, 8H), 1.03–1.35 (m, 7H), 
1.44–1.72 (m, 7H), 1.73–2.00 (m, 4H), 2.97–3.11 (m, 1H), 3.41–3.52 
(m, 1H), 4.13–4.24 (m, 1H), 4.43 (d, J = 13 Hz, minor) and 4.51 (d, J 
= 13 Hz, major, 1H), 4.55–4.64 (m, 1H), 4.64–4.71 (m, 1H), 6.84 (d, J 
= 5.6 Hz, major) and 7.06 (d, J = 5.6 Hz, minor, 1H), 7.12–7.26 (m, 
3H), 7.29–7.37 (m, 2H), 7.86–8.00 (m, 1H), 8.32 (d, J = 9.2 Hz, minor) 
and 8.43 (d, J = 9.2 Hz, major, 1H).    
23  
tR = 13.1 min (Method II); HRMS: calc. for C33H44N3O3S+ [MH]+ 
562.3098, found 562.3096; 1H NMR (600 MHz, DMSO-d6) (two 
rotamers in a ratio of 2:1) δ 0.77–1.01 (m, 8H), 1.02–1.42 (m, 7H), 
1.45–1.76 (m, 8H), 1.77–2.02 (m, 3H), 2.97–3.11 (m, 1H), 4.12–4.24 
(m, 1H), 4.40 (d, J = 13.6 Hz, minor) and 4.50 (d, J = 13.6 Hz, major, 
1H), 4.52–4.59 (m, 1H), 4.65–4.72 (m, 1H), 6.84 (d, J = 5.6 Hz, major) 
and 7.05 (d, J = 5.6 Hz, minor, 1H), 7.11–7.26 (m, 4H), 7.29–7.36 (m, 
2H), 7.77 (d, J = 5.1 Hz, 1H), 7.86–7.92 (m, 1H), 7.97 (d, J = 9.0 Hz, 
minor) and 8.11 (d, J = 9.0 Hz, major, 1H), 8.45–8.53 (m, 1H).  
24 
 
tR = 9.9 min (Method II); HRMS: calc. for C32H44N5O3+ [MH]+ 
546.3439, found 546.3438; 1H NMR (600 MHz, DMSO-d6) (two 
rotamers in a ratio of 2:1) δ  
25 
 
tR = 7.3 min (Method II); HRMS: calc. for C34H45N4O3+ [MH]+ 
557.3486, found 557.3494; 1H NMR (400 MHz, CDCl3) (two rotamers 
in a ratio of 1:1) δ 0.85–0.95 (m, 4H), 0.98–1.04 (m, 2H), 1.05–1.08 
(m, 4H), 1.38–1.58 (m, 4H), 1.64–1.85 (m, 10H), 1.91–2.14 (m, 2H), 
3.03–3.12 (m, 1H), 3.41–3.51 (m, 1H), 4.12–4.18 (m, 1H), 4.63–4.71 
(m, 1H), 4.75–4.83 (m, 1H), 4.91–4.97 (m, 1H), 6.82–6.93 (m, 4H), 
7.19–7.29 (m, 3H), 7.33–7.40 (m, 2H), 8.11–8.15 (m, 1H), 8.73 (dt, 
1H, J = 1.6, 4.8 Hz), 9.03 (t, 1H, J = 2.4 Hz); 13C NMR (100 MHz, 
CDCl3) δ 11.6/11.9 (Ile-d-CH3), 16.1/16.4 (Ile-g-CH3), 24.2 (Ile-g-
CH2), 26.3(1)/26.3(5), 26.4(2)/26.4(7), 26.5(4), 33.0/33.1, 33.5/33.6, 
33.9, 34.4(2)/34.4(5), 34.5(3), 38.4(7)/38.5(1), 40.5(7)/40.6(3), 41.3 
(br), 44.9/45.3, 51.9 (br), 52.1/52.3, 53.2/53.3/53.4 (2 ´ a-CH), 
121.7(0)/121.8(7)/121.9(4), 123.7, 125.8, 127.4(8)/127.5(5), 130.0, 
131.1, 135.3, 139.8/139.9, 142.8/143.0, 148.4, 151.0(9)/151.1(3), 
152.6, 165.5, 170.1(6)/170.2(0), 172.0/172.1. 
26 
 
tR = 12.9 min (Method IV); HRMS: calc. for C34H46N5O3+ [MH]+ 
572.3595, found 572.3599; 1H NMR (600 MHz, DMSO-d6) (two 
rotamers in a ratio of 1:1.3) δ 0.77–1.00 (m, 8H), 1.01–1.42 (m, 8H), 
1.45–1.56 (m, 1H), 1.56–1.77 (m, 7H), 1.77–2.00 (m, 3H), 2.98–3.12 
(m, 1H), 3.41–3.49 (m, 1H), 4.09–4.23 (m, 2H), 4.41 (d, J = 13 Hz, 
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minor) and 4.51 (d, J = 13 Hz, minor, 1H), 4.53–4.62 (m, 1H), 4.62–
4.70 (m, 1H), 6.84 (d, J = 5.7 Hz, major) and 7.05 (d, J = 5.7 Hz, 
minor, 1H), 6.95 (d, J = 9.3 Hz, 1H), 7.11–7.28 (m, 3H), 7.35 (d, J = 
7.2 Hz, 1H), 8.07 (d, J = 9.1 Hz, 0.4H), 8.19–8.29 (m, 2H), 8.48–8.57 
(m, 2H).    
27 
 
tR = 11.6 min (Method II); HRMS: calc. for C33H44N5O3+ [MH]+ 
558.3439, found 558.3440; 1H NMR (400 MHz, CDCl3) (two rotamers 
in a ratio of 1:1) δ 0.86–1.05 (m, 7H), 1.12–1.28 (m, 4H), 1.40–1.57 
(m, 4H), 1.66–1.89 (m, 9H), 1.91–2.21 (m, 2H), 3.04–3.17 (m, 1H), 
3.44–3.58 (m, 1H), 4.18–4.26 (m, 1H), 4.62–4.78 (m, 2H), 4.91–4.97 
(m, 1H), 6.83–6.87 (m, 2H), 7.13–7.30 (m, 4H), 7.34–7.37 (m, 1H), 
8.17–8.20 (m, 1H), 8.60 (br s, 1H), 8.78 (br s, 1H), 9.41 (br s, 1H); 13C 
NMR (100 MHz, CDCl3) δ 11.4/11.6 (Ile-d-CH3), 15.9/16.3 (Ile-g-
CH3), 24.4 (Ile-g-CH2), 26.2(2)/26.2(5), 26.3(6)/26.3(9), 26.5, 
32.6(9)/32.7(4), 33.5/33.6, 33.9, 34.4/34.5, 38.0/38.1, 40.1(5)/40.2(0), 
41.7/41.8, 45.3/45.7, 51.7(1)/51.7(5), 51.8(2)/51.8(7), 52.0/52.2, 
53.2/53.3/53.4 (2 ´ a-CH), 121.7/121.8, 121.9(7)/122.0(0), 
125.8/125.9, 127.5/127.6, 131.1(9)/131.2(5), 139.6/139.9, 142.8/143.0, 
143.1, 144.4, 147.4,, 150.9/151.0, 163.2, 170.7, 172.4. 
28 
 
tR = 15.0 min (Method I); HRMS: calc. for C39H49N4O4+ [MH]+ 
637.3748, found 637.3752; 1H NMR (400 MHz, CDCl3) (two rotamers 
in a ratio of 1:1) δ 0.86–1.06 (m, 7H), 1.09–1.30 (m, 4H), 1.36–1.55 
(m, 4H), 1.61–1.76 (m, 5H), 1.80–1.89 (m, 3H), 1.94–2.20 (m, 3H), 
2.41 (s, 3H), 3.02–3.16 (m, 1H), 3.42–3.55 (m, 1H), 4.13–4.23 (m, 
1H), 4.60–4.76 (m, 2H), 4.90–4.98 (m, 1H), 6.83–6.86 (m, 2H), 6.92–
7.04 (m, 4H), 7.19–7.36 (m, 6H), 7.66–7.70 (m, 1H).  
29 
 
tR = 12.1 min (Method I); HRMS: calc. for C37H47N4O3+ [MH]+ 
595.3643, found 595.3644; 1H NMR (400 MHz, CDCl3) (two rotamers 
in a ratio of 1:1) δ 0.86 (t, 2H, J = 7.2 Hz), 0.89–0.95 (m, 4H), 0.96–
1.08 (m, 3H), 1.10–1.30 (m, 4H), 1.36–1.67 (m, 5H), 1.68–2.07 (m, 
9H), 3.04–3.14 (m, 1H), 3.43–3.54 (m, 1H), 4.14–4.24 (m, 1H), 4.61–
4.74 (m, 1H), 4.80–4.89 (m, 1H), 4.91–4.98 (m, 1H), 6.66–6.74 (m, 
1H), 6.81–6.88 (m, 2H), 7.17–7.24 (m, 2H), 7.26–7.30 (m, 3H), 7.30–
7.36 (m, 2H), 7.41–7.46 (m, 1H), 7.86 (t, 1 H, J = 3.2Hz), 7.98–8.03 
(m, 1H), 8.65 (br s, 1H).  
30 
 
tR = 12.8 min (Method I); HRMS: calc. for C37H49NaN3O5+ [M+Na]+ 
638.3564, found 38.3573; 1H NMR (400 MHz, CDCl3) (two rotamers 
in a ratio of 1:1) δ 0.85–1.03 (m, 9H), 1.08–1.28 (m, 5H), 1.37–1.52 
(m, 4H), 1.61–1.89 (m, 5H), 1.92–2.13 (m, 2H), 3.30–3.13 (m, 1H), 
3.41–3.52 (m, 1H), 3.83 (s, 6H), 4.10–4.19 (m, 1H), 4.62–4.78 (m, 
2H), 4.89–4.96 (m, 1H), 6.58–6.63 (m, 2H), 6.82–6.92 (m, 3H), 7.19–
7.36 (m, 6H).  
31 
 
tR = 10.3 min (Method I); HRMS: calc. for C36H47N4O3+ [MH]+ 
583.3643, found 583.3645; 1H NMR (400 MHz, DMSO–d6) (two 
rotamers in a ratio of 1:1) δ 0.80–0.96 (m, 8H), 1.03–1.32 (m, 7H), 
1.47–1.70 (m, 7H), 1.74–2.00 (m, 4H), 2.97–3.10 (m, 1H), 3.45 (t, 1H, 
J = 12.8 Hz), 4.13–4.20 (m, 1H), 4.40 (d, 1H, J = 14 Hz), 4.48–4.60 
(m, 1H), 4.63–4.67 (m, 1H), 6.82 (d, 1H, J = 5.6 Hz), 6.89 (d, 1H, J = 
16 Hz), 7.11–7.34 (m, 5H), 7.49 (d, 1H, J = 15.6 Hz), 7.59 (dd, 1H, J = 
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5.2, 7.6 Hz), 8.15 (d, 1H, J= 8 Hz), 8.22 (d, 1H, J = 9.2 Hz), 8.29–8.36 
(m, 1H), 8.61 (s, 1H), 8.84 (s, 1H). 
32  
tR = 12.2 min (Method I); HRMS: calc. for C32H48N3O3+ [MH]+ 
522.3690, found 522.3698; 1H NMR (400 MHz, CDCl3) (two rotamers 
in a ratio of 1:1) δ 0.87–1.01 (m, 8H), 1.07–1.33 (m, 4H), 1.37–1.58 
(m, 3H), 1.64–1.72 (m, 5H), 1.78–2.11 (m, 11H), 2.18–2.23 (m, 2H), 
3.02–3.12 (m, 1H), 3.41–3.51 (m, 1H), 4.11–4.17 (m, 1H), 4.50–4.71 
(m, 2H), 4.86–4.92 (m, 1H), 5.95 (t, 1H, J = 6.4 Hz), 6.78–6.87 (m, 
2H), 7.20–7.35 (m, 6H). 
33  
tR = 5.4 min (Method II); HRMS: calc. for C30H45N4O3+ [MH]+ 
509.3486, found 509.3492; 1H NMR (400 MHz, CDCl3) (two rotamers 
in a ratio of 1:1) δ 0.81–0.95 (m, 7H), 1.06–1.19 (m, 4H), 1.25–1.46 
(m, 4H), 1.56–1.71 (m, 7H), 1.75–2.10 (m, 4H), 2.97–3.04 (m, 1H), 
3.37–3.47 (m, 1H), 3.72–3.76 (m, 1H), 3.97–4.02 (m, 1H), 4.15–4.20 
(m, 1H), 4.51–4.60 (m, 2H), 4.83–4.92 (m, 1H), 6.78 (d, 2H, J = 2 Hz), 
7.13–7.34 (m, 6H), 7.55 (br s, 1 H), 8.28–8.46 (br d, 1H).  
34  
tR = 8.1 min (Method IV). HRMS: calc. for C32H49N4O3+ [MH]+ 
537.3799, found 537.3790; 1H NMR (400 MHz, CDCl3) (two rotamers 
in a ratio of 1:1), δ 0.83–0.98 (m, 8H), 1.06–2.15 (m, 20H), 2.41–2.57 
(m, 2H, COCH2), 2.99–3.10 (m, 3H, CH2NH3+ and 1 ´ H of piperidine-
CH2), 3.41–3.51 (m, 1H, piperidine-CH2), 4.16–4.23 (m, 1H, 
piperidine-CH2), 4.47–4.61 (m, 2H, a-CH and piperidine-CH2), 4.84–
4.91 (m, 1H, a-CH), 6.82 (s, 2H, indene 2 ´ CH), 7.18–7.34 (m, 4H), 
7.41–7.53 (m, 2H, exchangeable with D2O), 8.06 (br s, 3H, 
exchangeable with D2O, NH3+);  13C NMR (100 MHz, CDCl3) δ 
10.9/11.1 (Ile-d-CH3), 15.5/15.8 (Ile-g-CH3), 22.8, 24.1, 25.9, 26.1, 
26.3, 32.2(8)/32.3(2), 33.2/33.4, 33.4(8)/33.5(3), 
34.0(5)/34.1(1)/34.1(6), 37.5/37.6, 39.3, 39.6(6)/39.7(4), 41.3 (s-syn	
amide piperidine NCH2), 45.0/45.4 (s-anti amide piperidine NCH2),	
51.7/51.9 (spiro-C), 52.3/52.5 (a-CH), 52.8(6)/52.9(0) (a-CH), 
121.4/121.6 (CH), 121.7/121.8 (CH), 125.5/125.7 (CH), 127.3/127.4 
(CH), 130.9(8)/131.0(2) (indene-CH), 139.3/139.5 (indene-CH), 
142.5/142.7 (C), 150.6(6)/150.7(3) (C), 170.7 (C), 172.7/172.9 (C), 
173.2/173.3 (C). 
35  
tR = 5.2 min (Method II); HRMS: calc. for C32H49N4O4+ [MH]+ 
553.3748, found 553.3748; 1H NMR (400 MHz, CDCl3) (two rotamers 
in a ratio of 1:1) δ 0.83–0.99 (m, 7H), 1.05–1.29 (m, 4H), 1.31–1.47 
(m, 3H), 1.48–1.58 (m, 2H), 1.61–1.76 (m, 5H), 1.77–1.91 (m, 3H), 
1.93–2.04 (m, 2H), 2.35–2.46 (m, 2H), 2.81–2.90 (m, 1H), 2.98–3.11 
(m, 1H), 3.20–3.34 (m, 2H), 3.39–3.58 (m, 1H), 4.28–4.41 (m, 1H), 
4.44–4.57 (m, 2H), 4.77–4.88 (m, 1H), 6.81 (br s, 2H), 7.18–7.43 (m, 
6H), 7.89–7.94 (m, 1H), 8.07 (br s, 2H).  
36 
 
tR = 9.7 min (Method I); HRMS: calc. for C31H47N4O4+ [MH]+ 539.3592, 
found 539.3589; 1H NMR (400 MHz, CDCl3) (two rotamers in a ratio 
of 1:1) δ 0.81–0.96 (m, 8H), 1.06–2.15 (m, 18H), 2.93–3.07 (m, 1H), 
3.36–3.54 (m, 1H), 3.92–4.17 (m, 3H), 4.28–4.55 (m, 3H), 4.80–4.89 
(m, 1H), 6.71–6.86 (m, 2H), 7.12–7.29 (m, 6H), 7.34–7.47 (m, 2H).  
37 
 
tR = 8.7 min (5 to 100%B in 15 min); HRMS: calc. for C31H48N5O3+ 
[MH]+ 538.3752, found 538.3752; 1H NMR (400 MHz, CDCl3) (two 
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rotamers in a ratio of 1:1), δ 0.80–0.96 (m, 8H), 1.02–1.22 (m, 4H), 
1.26–2.08 (m, 14H), 2.95–3.08 (m, 1H, 1 ´ H of piperidine-CH2), 3.41 
(br m, 1H, 1 ´ of piperidine-CH2), 3.55 (br m, 1H, 1 ´ H of Dap-b-
CH2), 3.75 (br m, 1H, 1 ´ H of Dap-b-CH2), 4.04 (br s, 1H, 1 ´ H of 
piperidine-CH2), 4.61–4.36 (m, 3H, 2 ´ a-CH and 1 ´ H of piperidine-
CH2), 4.80–4.88 (m, 1H, a-CH), 6.75–6.83 (m, 2H), 7.12–7.30 (m, 
4H), 7.31–9.60 (6H, incl. 1 ´ very br s at δ 8.50 and 3 ´ br s at δ 7.36, 
8.89 and 8.96). 
38 
 
tR = 9.6 min (5 to 100%B in 15 min); HRMS: calc. for C32H48N5O4+ 
[MH]+ 566.3701, found 566.3701; 1H NMR (400 MHz, CDCl3) (two 
rotamers in a ratio of 1:1) δ 0.81–0.98 (m, 8H), 1.02–1.23 (m, 4H), 
1.53–1.24 (m, 4H), 1.54–2.12 (m, 10H), 2.88–3.08 (m, 3H, 1 ´ H of 
piperidine-CH2 and Asn-b-CH2), 3.38–3.48 (m, 1H), 4.13–4.19 (m, 
1H), 4.46–4.62 (m, 3H, 2 ´ a-CH and 1 ´ H of piperidine-CH2), 4.82–
4.88 (m, 1H, a-CH), 6.75–6.82 (m, 2H), 7.00–7.32 (m, 4H), 7.52–8.72 
(m, 6H, incl. 1 ´ very br s at δ 8.32, 1 ´ br s at δ 7.58, and 3 ´ doublets 
at δ 7.65, J = 7.6 Hz, δ 8.59, J = 6.4 Hz and δ 8.70, J = 6.4 Hz). 
39  
tR = 5.6 min (Method II); HRMS: calc. for C33H49N4O3+ [MH]+ 
549.3799, found 549.3792; 1H NMR (400 MHz, CDCl3) (two rotamers 
in a ratio of 1:1) δ 0.83–0.98 (m, 9H), 1.07–1.23 (m, 4H), 1.37–1.50 
(m, 3H), 1.60–1.75 (m, 7H), 1.88–2.14 (m, 5H), 2.40–2.53 (m, 2H), 
3.00–3.09 (m, 1H), 3.40–3.50 (m, 3H), 4.11–4.21 (m, 1H), 4.52–4.69 
(m, 2H), 4.71–4.80 (m, 1H), 4.87–4.99 (m, 1H), 6.80–6.85 (m, 2H), 
7.17–7.29 (m, 4H), 7.29–7.36 (m, 1H), 7.37–7.47 (m, 1H), 7.90–8.0 
(m, 1H).  
40 
 
tR = 8.3 min (Method II); HRMS: calc. for C33H47N4O4+ [MH]+ 
563.3592, found 563.3598; 1H NMR (400 MHz, CDCl3) (two rotamers 
in a ratio of 1:1) δ 0.87–1.03 (m, 7H), 1.09–1.31 (m, 5H), 1.38–1.57 
(m, 4H), 1.58–1.84 (m, 7H), 1.90–2.04 (m, 2H), 2.06–2.30 (m, 2H), 
2.39–2.59 (m, 3H), 3.04–3.14 (m, 1H), 3.44–3.55 (m, 1H), 4.15–4.28 
(m, 2H), 4.53–4.68 (m, 2H), 4.90–4.95 (m, 1H), 6.81–6.86 (m, 2H), 
6.99–7.01 (m, 1H), 7.20–7.39 (m, 6H).  
41  
Rt = 9.8 min (Method I); HRMS: calc. for C34H51N4O3+ [MH]+ 
563.3956, found 563.3956; 1H NMR (400 MHz, CDCl3) (two rotamers 
in a ratio of 1:1) δ 0.85–0.99 (m, 7H), 1.15–1.27 (m, 7H), 1.33–1.55 
(m, 4H), 1.88–2.17 (m, 12H), 2.50–2.63 (m, 1H), 2.98–3.04 (m, 3H), 
3.40–3.57 (m, 3H), 4.13–4.19 (m, 1H), 4.53–4.65 (m, 2H), 4.89 (q, 1H, 
J = 8.4 Hz), 6.73–6.77 (m, 1H), 6.80–6.85 (m, 2H), 7.17–7.35 (m, 6H).  
42 
 
V= 8.0 min (Method IV); HRMS: calc. for C32H47N6O3+ [MH]+ 
563.3704, found 563.3704; 1H NMR (400 MHz, CDCl3) (two rotamers 
in a ratio of 64:36) δ 0.84–0.99 (m, 8H), 1.06–2.12 (m, 18H), 3.00–
3.07 (m, 1H), 3.39–3.50 (m, 1H), 3.84 (br s, 1H), 3.92–3.99 (m, 1H), 
4.11–4.20 (m, 1H), 4.38–4.48 (m, 1H), 4.52–4.59 (m, 2H), 4.79–4.87 
(m, 1H), 6.79–6.83 (m, 2H), 7.16–7.34 (m, 4H), 7.40 (br m, 1H), 7.83 
(br s, 2H), 8.00 (d, 0.36H, J = 7.2 Hz), 8.09 (d, 0.36H, J = 6.0 Hz), 8.35 
(br s, 0.64H), 8.69 (br s, 0.64H); 13C NMR (100 MHz, CDCl3) δ 
11.2/11.5 (Ile-d-CH3), 15.8/16.1 (Ile-g-CH3), 24.2(8)/24.3(3), 26.2, 
26.4, 32.6(7)/32.6(9), 33.3(8)/33.4(4), 33.4(8)/33.5(2), 34.3/34.4, 37.7, 
39.4, 41.4/41.5, 45.1/45.5, 47.2/47.3, 51.9/52.1, 53.0/53.2, 53.4/53.5, 
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57.2(6)/57.2(9), 121.5/121.8, 121.9, 125.7/125.8, 127.4/127.5, 
131.1/131.2, 139.6/139.7, 142.7/142.9, 150.9/151.0, 160.5, 
170.6/170.7, 172.7/172.9. 
 
ID R2 Analytical data 
43 
 
tR 9.2 min (Method II); HRMS: calc. for C29H39N4O4+ [MH]+ 507.2966, 
found 507.2965; 1H NMR (400 MHz, CDCl3) (two rotamers in a ratio 
of 57:43) δ 0.86–0.95 (m, 5H), 1.00 (d, 1H, J = 6.8 Hz), 1.07 (s, 4H), 
1.13 (s, 5H), 1.39–1.60 (m, 2H), 1.79–1.88 (m, 1H), 1.90–2.04 (m, 
2H), 2.10–2.20 (m, 2H), 3.02–3.17 (m, 1H), 3.43–3.57 (m, 1H), 4.12–
4.27 (m, 1H), 4.50–4.75 (m, 2H), 4.92–4.98 (m, 1H), 6.83–6.88 (m, 
2H), 6.97–6.98 (m, 1H), 7.20–7.35 (m, 6H), 8.34 (d, 1H, J = 2.0 Hz).  
44 
 
tR 10.0 min (0% to100% B in 10 min, then 100%B for extra 5min); 
HRMS: calc. for C30H40N5O5+ [MH]+ 550.3024, found 550.3022; 1H 
NMR (400 MHz, CDCl3) (two rotamers in a ratio of 1:1) δ 0.85–1.54 
(m, 10H), 1.80–2.22 (m, 3H), 3.06–3.13 (m, 1H), 3.37 (br s, 4H), 3.45–
3.55 (m, 1H), 3.65–3.71 (m, 1H), 3.83–3.92 (m, 1H), 3.99 (s, 4H), 4.14 
(d, 1H, J = 12Hz), 4.58–4.66 (m, 1H), 4.80–4.85 (m, 1H), 5.26–5.34 
(m, 1H), 6.81–6.86 (m, 2H), 6.99 (d)/7.00 (d, J = 1.6 Hz, 1H), 7.19–
7.37 (m, 4H), 7.96 (d, 1H, J = 6.8 Hz), 8.34 (d)/8.35 (d, J = 1.6 Hz, 
1H), 8.77–8.82 (m, 1H); 13C NMR (100 MHz,CDCl3) δ 11.4/11.6 (Ile-
d-CH3), 15.8/16.2 (Ile-g-CH3), 24.3 (Ile-g-CH2), 33.5/33.6, 34.2/34.3, 
37.4, 41.8/42.0, 45.2/45.7, 48.6, 51.9/52.1, 53.3, 54.6/54.7, 58.3/58.4, 
63.9, 107.5, 121.6/121.9, 122.0, 125.8/125.9, 127.6/127.7, 131.4, 
139.5/139.6, 142.8/142.9, 150.8/150.9, 151.1, 157.0, 161.6, 167.8, 
170.7. 
45 
 
tR = 11.4 min (Method II); HRMS: calc. for C33H45N4O4+ [MH]+ 
561.3435, found 561.3438; 1H NMR (400 MHz, CDCl3) (two rotamers 
in a ratio of 1:1) δ 0.84–0.96 (m, 6H), 1.02 (d, 1H, J = 6.4 Hz), 1.09–
1.32 (m, 7H), 1.40–1.57 (m, 3H), 1.60–1.76 (m, 5H), 1.78–1.87 (m, 
2H), 1.90–2.05 (m, 3H), 2.10–2.18 (m, 1H), 3.04–3.16 (m, 1H), 3.44–
3.57 (m, 1H), 4.15–4.23 (m, 1H), 4.58–4.73 (m, 2H), 4.92–4.98 (m, 
1H), 6.83–6.87 (m, 2H), 6.94 (t, 1H, J = 2.0 Hz), 7.03 (dd, 1H, J = 8.8 
Hz, 16.6 Hz), 7.20–7.36 (m, 5H), 8.34–8.35 (m, 1H).  
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46: tR 8.7 min (Method II); HRMS: calc. for C30H39N4O4+ [MH]+ 519.2966, found 519.2968; 1H 
NMR (CDCl3) (two rotamers in a ratio of 1:1) δ 0.90–1.03 (m, 2H), 1.10–1.29 (m, 3H), 1.35–
1.42 (m, 3H), 1.65–1.72 (m, 12H), 1.75–1.86 (m, 3H), 1.96–2.17 (m, 2H), 3.23 (br s, 1H), 4.48 
(br s, 1H), 4.60–4.64 (m, 1H), 6.79–6.81 (m, 2H), 6.87 (d, 1H, J = 1.2 Hz), 7.08–7.12 (m, 1H), 
7.16–7.18 (m, 1 H), 7.23–7.26 (m, 2H), 7.32 (d, 1H, J = 6.6 Hz), 7.44 (br s, 1H), 8.31 (d, 1H, J = 
1.8 Hz). 
 
 
ID R3 Analytical data 
 
47  
tR = 11.1 min (Method II); HRMS: calc. for C32H43N4O4+ [MH]+ 547.3279, 
found 547.3278; 1H NMR (600MHz, CDCl3, two rotamers in a ratio of 3:2) δ 
0.92–1.08 (m, 12H), 1.11–1.36 (m, 4H), 1.36–1.46 (m, 2H), 1.46–1.52 (m, 
1H), 1.63–1.77 (m, 6H), 1.77–1.87 (m, 2H), 1.91–2.09 (m, 2H), 2.99–3.04 
(m, 0.6H)/3.09–3.14 (m, 0.4H), 3.41–3.46 (m, 0.6H)/3.49–3.54 (m, 0.4H), 
4.20–4.25 (m, 1H), 4.61–4.75 (m, 2H), 4.96 (d, 0.4H, J = 9.6 Hz)/ 4.99 (d, 
0.6H, J = 9.6 Hz), 6.71–6.88 (m, 3H), 6.94–6.95 (m, 1H), 7.05 (dd, 1H, J = 
7.8, 17.4 Hz), 7.19–7.23 (m, 1H), 7.27–7.32 (m, 1H), 7.33–7.37 (m, 1H), 
8.34 (d, 1H, J = 1.8 Hz). 
48 
 
tR = 11.9 min (Method II); HRMS: calc. for C35H47N4O4+ [MH]+ 587.3592, 
found 587.3588; 1H NMR (400MHz, CDCl3) (two rotamers in a ratio of 1:1) 
δ 0.84–1.07 (m, 4H), 1.08–1.28 (m, 6H), 1.30–1.56 (m, 5H), 1.57–1.91 (m, 
12H), 1.95–2.20 (m, 3H), 3.01–3.15 (m, 1H), 3.40–3.56 (m, 1H), 4.04–4.12 
(m, 1H), 4.58–4.75 (m, 1H), 5.07–5.15 (m, 1H), 6.82–6.86 (m, 1H), 6.94–
6.95 (m, 1H), 6.99–7.04 (m, 1H), 7.10–7.15 (m, 1H), 7.20–7.36 (m, 4H), 
8.34 (dd, 1H, J = 0.8, 1.6 Hz). 
49 
 
tR = 11.1 min (Method II); HRMS: calc. for C30H39N4O5+ [MH]+ 535.2915, 
found 535.2915; 1H NMR (400MHz, CDCl3) (two rotamers in a ratio of 1:1) 
δ 0.86–1.28 (m, 8H), 1.34–2.14 (m, 12H), 2.84–3.33 (m, 2H), 3.42–3.64 (m, 
1H), 4.06–4.13 (m, 1H), 4.52–4.62 (m, 1H), 4.91––4.97 (m, 1H), 5.16–5.22 
(m, 1H), 6.80–6.94 (m, 2H), 6.96 (d, 1H, J = 2.0 Hz), 7.11–7.67 (m, 6H), 
8.35 (d, 1H, J = 2.0 Hz). 
50 
 
tR = 9.2 min (Method II); HRMS: calc. for C31H41N4O5+ [MH]+ 549.3071, 
found 549.3072; 1H NMR (400 MHz, CDCl3, two rotamers in a ratio of 1:1) 
δ 0.88–1.32 (m, 8H), 1.36–1.50 (m, 3H), 1.63–2.16 (m, 9H), 3.07–3.17 (m, 
1H, s-syn amide piperidine NCH2), 3.35 (s)/3.40 (s, 3H, OCH3), 3.44–3.53 
(m, 1H, s-anti amide piperidine NCH2), 3.66 (m, 1H, Thr-b-CH), 4.17 (br s, 
1H, s-anti amide piperidine NCH2), 4.65–4.72 (m, 1H, s-syn amide piperidine 
NCH2), 4.72–4.79 (m, 1H, Cha-a-CH), 5.12 (dd, 1H, J = 8.0, 4.0 Hz, Thr-a-
CH), 6.83 (d, 1H, J = 6.0 Hz, indene-CH), 6.85 (d, 1H, J = 6.0 Hz, indene-
CH), 6.96 (d, 1H, J = 1.6 Hz, isoxazole-CH), 7.40–7.19 (m, 6H), 8.35 (d, 1H, 
J = 2.0 Hz, isoxazole-CH); 13C NMR (100 MHz,CDCl3) δ 15.1/15.2 (Thr-g-
CH3), 25.9, 26.1(0)/26.1(4), 26.3, 32.3, 33.2/33.4, 33.7, 34.0, 40.1, 41.6/41.8 
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(s-syn amide piperidine NCH2), 45.2/45.6 (s-anti amide piperidine NCH2), 
51.4 (Cha-a-CH), 51.8/52.0 (spiro-C), 52.7/52.9 (Thr-a-CH), 56.9 (OCH3), 
106.9 (isoxazole-CH), 121.5/121.6 (CH), 121.7 (CH), 125.5/125.6 (CH), 
127.3 (CH), 130.9(6)/131.0(0) (indene-CH), 139.5/139.6 (indene-CH), 
142.6/142.7, 150.7(6)/150.8(4), 151.0(4) (isoxazole-CH), 155.7, 162.2, 
168.1/168.2, 171.6/171.8. 
51 
 
tR = 10.1 min (Method I); HRMS: calc. for C30H40N5O4+ [MH]+ 534.3075, 
found 534.3070; 1H NMR (400 MHz, CDCl3) (two rotamers in a ratio of 1:1) 
δ 0.82–1.22 (m, 5H), 1.32–1.48 (m, 2H), 1.54–1.82 (m, 8H), 1.92–2.08 (m, 
3H), 2.20–2.38 (m, 1H), 2.82–3.20 (m, 3H), 3.38–3.46 (m, 1H), 3.90–4.08 
(m, 1H), 4.46–4.74 (m, 2H), 5.04–5.14 (m, 1H), 6.74–6.83 (m, 2H), 6.91 (br 
s, 1H), 7.14–7.33 (m, 4H), 8.0–8.17 (br m, 5H), 8.27 (s, 1H); 13C NMR (100 
MHz,CDCl3) δ 25.9, 26.1, 26.2, 30.0/30.4, 32.1(5)/32.2(2), 33.1/33.2, 
33.5/33.6/33.8, 34.1, 36.1, 39.1/39.2, 41.5/41.6 (s-syn amide piperidine 
NCH2), 44.5/44.7 (s-anti amide piperidine NCH2), 47.0/47.1 (Dab-a-CH), 
51.7/51.8 (spiro-C), 51.9/52.0 (Cha-a-CH), 107.0 (isoxazole-CH), 
121.65(1)/121.6(0) (CH), 121.6(3)/121.6(9) (CH), 125.5/125.6 (CH), 127.3 
(CH), 130.9(6)/131.0(0) (indene-CH), 139.4 (indene-CH), 142.6/142.7, 
150.7/150.8, 151.2 (isoxazole-CH), 156.3(7)/156.4(1), 161.9(6)/162.0(4), 
168.6/168.8, 173.1/173.2. 
52 
 
tR = 10.1 min (Method I); HRMS: calc. for C30H38N5O5+ [MH]+ 548.2867, 
found 548.2869; 1H NMR (400 MHz, CDCl3) (two rotamers in a ratio of 1:1) 
δ 0.82–2.30 (m, 17H), 2.56–2.90 (m, 2H), 3.05–3.12 (m, 1H), 3.43–3.54 (m, 
1H), 4.06–4.12 (m, 1H), 4.48–4.64 (m, 2H), 5.26–5.34 (m, 1H), 6.06 (br s) 
and 6.17 (br s, 1H), 6.74–6.86(m, 3H), 6.93 (d, 1H, J = 1.2 Hz), 7.14–7.63 
(m, 6H), 8.35 (d, 1H, J = 1.2 Hz). 
53 
 
tR = 9.1 min (Method I); HRMS: calc. for C32H39N6O4+ [MH]+ 571.3027, 
found 571.3026; 1H NMR (400 MHz, CDCl3) (two rotamers in a ratio of 
54:46) δ 0.80–1.20 (m, 5H), 1.30–1.80 (m, 10H), 1.95–2.12 (m, 2H), 2.92–
3.30 (m, 3H, Hax of s-syn amide piperidine NCH2 and His-b-CH2), 3.44–3.58 
(m, 1H, Hax of s-anti amide piperidine NCH2), 3.96–4.12 (m, 1H, Heq of s-anti 
amide piperidine NCH2), 4.48–4.71 (m, 2H, Heq of s-syn amide piperidine 
NCH2 and Cha-a-CH), 5.24–5.33 (m, 1H, His-a-CH), 6.77–7.00 (m, 3H), 
7.14–7.35 (m, 6H), 7.85 (d, 1H, J = 7.6 Hz, Cha-NH), 8.02 (d, J = 8.0 Hz, 
major) and 8.04 (d, J = 8.4 Hz, minor, 1H, His-NH), 8.32 (d, 1H, J = 1.6 Hz, 
His-CH), 8.51 (br s, 1H, isoxazole-CH). 
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54 
 
tR = 7.2 and 7.8 min (Method II, two diastereomers in a ratio of 2:1); 
HRMS: calc. for C32H43N4O5+ [MH]+ 563.3228, found 563.3228; 1H 
NMR (400 MHz, CDCl3) δ 0.83-1.01 (m, 8H), 1.04–2.10 (m, 18H), 
3.03–3.12 (m, 1H, Hax of s-syn amide piperidine NCH2), 3.48–3.60 
(m, 1H, Hax of s-anti amide piperidine NCH2), 4.08–4.22 (m, 2H, 
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incl. 1 ´ epoxide-CH and Heq of s-anti amide piperidine NCH2), 4.30 
(d, 1H, J = 2.4 Hz, 1 ´ epoxide-CH), 4.60–4.78 (m, 1H, Heq of s-syn 
amide piperidine NCH2), 4.78–4.86 (m, 1H), 4.92–5.03 (m, 1H), 
6.96 (m, 1H, isoxazole-CH), 7.05–7.53 (m, 6H, 4 ´ PhCH and 2 ´ 
NH), 8.32 (m, 1H, isoxazole-CH). 
55 
 
tR = 9.9 min (Method II); HRMS: calc. for C32H45N5NaO6S+ 
[M+Na]+ 650.2983, found 650.2985; 1H NMR (400 MHz, CDCl3) 
(two rotamers in a ratio of 2:1) δ 0.85–1.03 (m, 8H), 1.09–2.10 (m, 
18H), 2.80–2.93 (m, 1H, Hax of s-syn amide piperidine NCH2), 
2.94(s)/2.93(s, 3H, SO2Me), 3.24–3.41 (m, 1H, Hax of s-anti amide 
piperidine NCH2), 3.86–3.93 (m, 2H, indole-NCH2), 4.14–4.24 (m, 
1H, Heq of s-anti amide piperidine NCH2), 4.56–4.74 (m, 2H, Cha-a-
CH and Heq of s-syn amide piperidine NCH2), 4.87–4.91 (m, 1H, Ile-
a-CH), 6.95 (d, J = 2.0 Hz, major) and 6.96 (d, J = 2.0 Hz, minor, 
1H, isoxazole-CH), 7.05–7.31 (m, 4H), 7.37–7.42 (m, 1H, NH), 7.45 
(d, J =8.8 Hz, minor) and 7.55 (d, J = 8.8 Hz, major, 1H, NH), 8.35 
(d, 1H, J = 2.0 Hz, isoxazole-CH). 
56 
 
tR = 9.6 min (Method II); HRMS: calc. for C31H40N4NaO6+ [M+Na]+ 
587.2840, found 587.2843; 1H NMR (400 MHz, CDCl3) (two 
rotamers in a ratio of 72:28) δ 0.88–1.90 (m, 24H), 2.00–2.16 (m, 
1H, 1 ´ H of s-syn amide piperidine NCH2CH2), 2.29–2.37 (m, 1H, 
1 ´ H of s-anti amide piperidine NCH2CH2), 3.14–3.24 (m, 1H, Hax 
of s-syn amide piperidine NCH2), 3.63–3.71 (m, 1H, Hax of s-anti 
amide piperidine NCH2), 4.17–4.21 (m, 1 H, Heq of s-anti amide 
piperidine NCH2), 4.66–4.76 (m, 2H, Cha-a-CH and Heq of s-syn 
amide piperidine NCH2), 4.89–4.94 (m, 1H, Ile-a-CH), 6.95 (d, 1H, 
J = 2.0Hz), 6.88 (d, 0.28H, J = 8.8Hz) and 7.03 (d, 0.72H, J = 8.8 
Hz, Ile-NH), 7.16–7.21 (m, 1H, Cha-NH), 7.35 (d, 0.28H, J = 
8.0Hz) and 7.45 (d, 0.72H, J = 8.0 Hz), 7.54–7.60 (m, 1H), 7.68–
7.73 (m, 1H), 7.90–7.95 (m, 1H), 8.35 (d, 0.28H, J = 2.0 Hz) and 
8.36 (d, 1H, 0.72H, J = 2.0 Hz, isoxazole-CH). 
57 
 
tR = 10.4 min (Method II); HRMS: calc. for C32H43N4O6+ [MH]+ 
579.3177, found 579.3178; 1H NMR (400 MHz, CDCl3) (two 
rotamers in a ratio of 55:45) δ 0.85–1.08 (m, 8H), 1.03–1.40 (m, 
5H), 1.43–1.84 (m, 11H), 2.11–2.24 (m, 2H), 2.71-2.82 (m, 2H, 
benzopyranone-CH2), 3.10–3.26 (m, 1H, Hax of s-syn amide 
piperidine NCH2), 3.56–3.69 (m, 1H, Hax of s-anti amide piperidine 
NCH2), 3.93–4.06 (m, 1H, Heq of s-anti amide piperidine NCH2), 
4.37–4.47 (m, 1H, Heq of s-syn amide piperidine NCH2), 4.62–4.72 
(m, 1H, Cha-a-CH), 4.85 (app t, 1H, J = 8.6 Hz, Ile-a-CH), 6.94 (d, 
J = 2.0 Hz) and 6.96 (d, J = 2.0 Hz, 1H, isoxazole-CH), 6.99–7.08 
(m, 2H), 7.18 (d, J = 7.6 Hz, major) and 7.23 (d, J = 8.0 Hz, minor, 
1H, Cha-NH), 7.36 (d, J = 9.2 Hz, minor) and 7.44 (d, J = 8.8 Hz, 
major, 1H, Ile-NH), 7.50–7.56 (m, 1H), 7.87–7.91 (m, 1H), 8.35 (d, 
1H, J = 2.0 Hz, isoxazole-CH).  
58 
 
tR = 10.6 min (Method II); HRMS: calc. for C32H45N4O5+ [MH]+ 
565.3384, found 565.3385; 1H NMR (400 MHz, CDCl3) (two 
rotamers in a ratio of 1:1) δ 0.85–1.00 (m, 8H), 1.11–1.24 (m, 6H), 
1.49–2.22 (m, 14H), 2.77–2.82 (m, 2H), 3.15–3.28 (m, 1H, Hax of s-
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syn amide piperidine NCH2), 3.57–3.69 (m, 1H, Hax of s-anti amide 
piperidine NCH2), 3.92–4.00 (m, 1H, Heq of s-anti amide piperidine 
NCH2), 4.40–4.47 (m, 1H, Heq of s-syn amide piperidine NCH2), 
4.68–4.76 (m, 1H, Cha-a-CH), 4.90 (t, 1H, J = 8.4 Hz, Ile-a-CH), 
6.82–7.14 (m, 5H), 7.31–7.58 (m, 2H, 2 ´ NH), 8.34 (d, 1H, J = 1.2 
Hz, isoxazole-CH).  
59 
 
tR = 9.1 min (Method II); HRMS: calc. for C30H43N4O6+ [MH]+ 
555.3177, found 555.3179; 1H NMR (400 MHz, DMSO-d6) (two 
rotamers in a ratio of 58:42) δ 0.89–1.98 (m, 22H), 2.75–2.95 (m, 
2H), 3.64–3.97 (m, 8H, including MeO singlets at δ 3.82 and 3.84), 
4.54–4.87 (m, 4H), 6.83 (s)/6.87 (s)/6.89 (s, 2H), 7.26 (d, J = 2.0 
Hz, minor) and 7.27 (d, J = 2.0 Hz, major, 1H, isoxazole-CH),  8.29 
(d, J = 8.8 Hz, minor) and 8.32 (d, J = 8.8 Hz, major, 1H, NH), 8.86 
(d, 1H, J = 2.0 Hz, isoxazole-CH), 9.00 (d, J = 8.0 Hz, minor) and 
9.01 (d, J = 8.0 Hz, major, 1H, NH). 
60 
 
tR = 13.6 min (Method II); HRMS: calc. for C33H54N5O5+ [MH]+ 
600.4119, found 600.4118; 1H NMR (400 MHz, DMSO-d6) (two 
rotamers in a ratio of 1:1) δ 0.76–0.91 (m, 8H), 0.97–1.36 (m, 18H), 
1.40–1.70 (m, 15H), 1.77–1.84 (m, 1H), 1.91–1.95 (m, 1H), 3.50 (t, 
1H, J = 12.4 Hz), 3.64 (dd, 1H, J = 4.4, 13.2 Hz), 4.41–4.54 (m, 
2H), 4.65 (t, 1H, J = 8.8 Hz), 4.78–4.81 (m, 1H), 7.12 (s, 1H), 7.13 
(d, 1H, J = 1.6 Hz), 8.11 (d, 1H, J = 8.8 Hz), 8.72 (d, 1H, J = 1.6 
Hz), 8.91 (d, 1H, J = 8.4 Hz).  
61 
 
tR = 9.3 min (Method II); HRMS: calc. for C29H48N5O5+ [MH]+ 
546.3650, found 546.3653; 1H NMR (400 MHz, DMSO-d6) (two 
rotamers in a ratio of 2:1) δ 0.76–0.92 (m, 10H), 0.97–1.23 (m, 6H), 
1.16–1.26 (m, 11H), 1.27–1.44 (m, 5H), 1.47–1.67 (m, 12H), 1.76–
1.81 (m, 1H), 1.95–1.98 (m, 1H), 3.92 (br d, 1H, J = 13.2 Hz), 4.49–
4.55 (m, 2H), 4.64 (t, 1H, J = 8.4 Hz), 4.92–4.94 (m, 1H), 7.04 (s, 
1H), 7.13 (d, 1H, J = 2.0 Hz), 8.06 (d, 1H, J = 2.0 Hz), 8.72 (d, 1H, 
J = 2.0 Hz), 8.91 (d, 1H, J = 8.4 Hz).  
62 
 
tR = 28.6 min (0% to 100% B linear gradient over 30 min followed 
by a further 10 min at 100% B); HRMS: calc. for C29H42N5O4+  
[MH]+524.3231, found 524.3243; 1H NMR (400 MHz, DMSO-d6) 
(two rotamers in a ratio of 1:1) 0.78-0.72 (m, 6H); 0.84–0.89 (m, 
2H), 1.02–1.11 (m, 4H), 1.22–1.30 (m, 1H), 1.45–1.64 (m, 8H), 
1.77–1.83 (m, 1H), 2.94–3.13 (m, 5H), 3.49–3.77 (m, 8H), 4.49–
4.55 (m, 1H), 4.59 (t, 1H, J = 8.6 Hz), 6.79 (t, 1H, J = 7.3 Hz), 6.92 
(d, 2H, J = 8.8 Hz), 7.10 (d, 1H, J = 4.0 Hz), 7.20 (dd, 1H, J = 7.3, 
8.7 Hz), 8.19 (d, 1H, J = 8.7 Hz), 8.88 (d, 1H, J = 8.3 Hz). 
63 
 
tR = 8.2 min (Method II); HRMS: calc. for C29H41FN5O4+ [MH]+ 
542.3137, found 542.3137; 1H NMR (400 MHz, CDCl3) (two 
rotamers in a ratio of 1:1) δ 0.85–1.02 (m, 8H), 1.07–1.29 (m, 4H), 
1.30–1.40 (m, 1H), 1.46–1.55 (m, 1H), 1.62–1.85 (m, 10H), 3.16–
3.36 (m, 4H), 3.68–3.73 (m, 1H), 3.80–3.87 (m, 1H), 4.01–4.07 (m, 
1H), 4.11–4.17 (m, 1H), 4.59–4.65 (m, 1H, Cha-a-CH), 4.80 (d, J = 
8.0 Hz) and 4.82 (d, J = 8.0 Hz, 1H, Ile-a-CH), 6.91 (d, 1H, J = 2.0 
Hz), 6.93–7.17 (m, 6H), 8.34 (d, 1H, J = 2.0 Hz). 
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tR = 5.7 min (Method II); HRMS: calc. for C30H43FN5O4+ [MH]+ 
556.3294, found 556.3291; 1H NMR (400 MHz, DMSO-d6) (two 
rotamers in a ratio of 1:1) δ 0.90–1.09 (m, 8H) 1.13–1.49 (m, 6H), 
1.52–1.94 (m, 10H), 2.82–3.18 (m, 4H), 3.58 (CH2Ar, overlapped 
with water peak), 4.38–4.58 (m, 4H), 4.59–4.64 (m, 1H, Cha-a-
CH), 4.65–4.70 (app t, 1H, J = 8.4 Hz, Ile-a-CH), 7.27 (s, 1H, 
isoxazole-CH), 7.43–7.45 (m, 2H), 7.65–7.67 (m, 2H), 8.28 (d, 1H, 
J = 8.0 Hz), 8.88 (s, 1H, isoxazole-CH), 9.05 (br s, 1H).  
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tR = 12.7 min (Method II); HRMS: calc. for C30H42ClN4O4+ [MH]+ 
577.2889, found 577.2894; 1H NMR (400 MHz, CDCl3) (two 
rotamers in a ratio of 1:1) δ 0.84–1.03 (m, 8H), 1.07–1.38 (m, 6H), 
1.44–2.00 (m, 12H), 2.66–2.79 (m, 2H, piperidine-CHAr and Hax of 
s-syn amide piperidine NCH2), 3.15–3.24 (m, 1H, Hax of s-anti 
amide piperidine NCH2), 4.12–4.19 (m, 1H, Heq of s-anti amide 
piperidine NCH2), 4.65–4.71 (m, 1H, a-CH), 4.74–4.79 (m, 1H, Heq 
of s-syn amide piperidine NCH2), 4.86–4.91 (m, 1H, a-CH), 6.74–
6.79 (m, 1H), 6.93 (d, 1H, J = 1.6 Hz, isoxazole-CH), 7.04–7.08 (m, 
1H), 7.10–7.14 (m, 2H), 7.27–7.30 (m, 2H), 8.33 (d, 1H, J = 2.0 Hz, 
isoxazole-CH).  
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tR = 11.7 min (Method II); HRMS: calc. for C31H45N4O5+ [MH]+ 
553.3384, found 553.3384; 1H NMR (400 MHz, CDCl3) (two 
rotamers in a ratio of 1:1) δ 0.84–1.03 (m, 8H), 1.06–1.36 (m, 5H), 
1.43–2.00 (m, 13H), 2.71–2.78 (m, 2H, piperidine-CHAr and Hax of 
s-syn amide piperidine NCH2), 3.17–3.22 (m, 1H, Hax of s-anti 
amide piperidine NCH2), 3.79 (s, 3H, OMe), 4.15–4.17 (m, 1H, Heq 
of s-anti amide piperidine NCH2), 4.65–4.70 (m, 1H, a-CH), 4.73–
4.77 (m, 1H, Heq of s-syn amide piperidine NCH2), 4.87–4.93 (m, 
1H, a-CH), 6.84–6.94 (m, 4H), 7.08–7.12 (m, 3H), 8.33 (d, 1H, J = 
2.0 Hz, isoxazole-CH); 13C NMR (100 MHz, CDCl3): 11.3/11.5 (Ile-
d-CH3), 15.7/16.1 (Ile-g-CH3), 24.0/24.1 (Ile-g-CH2), 26.0, 26.1, 
26.3 32.6/32.7, 33.1/33.3, 33.6, 34.0, 38.0(6)/38.1(1), 40.2, 
41.5/41.8, 43.1 (br s), 46.6/47.1, 51.4 (br s), 53.0/53.1/53.2, 
55.2/55.3, 106.8 (isoxazole-4-CH), 113.9(6)/140.0(1), 127.5/127.6, 
136.8/136.9, 151.0, 155.4, 158.2/158.3, 162.4, 169.9/170.0, 
171.1(5)/171.2(1). 
68 
 
tR = 11.4 min (Method II); HRMS: calc. for C32H47N4O6+ [MH]+ 
583.3490, found 583.3492; 1H NMR (600 MHz, CDCl3) (two 
rotamers in a ratio of 1:1) δ 0.84–0.93 (m, 6H), 0.93–1.01 (m, 3H), 
1.05–1.27 (m, 6H), 1.30–1.38 (m, 1H), 1.45–1.53 (m, 2H), 1.53–
1.84 (m, 13H), 1.86–2.00 (m, 4H), 2.72–2.76 (m, 1H, Hax of s-syn 
amide piperidine NCH2), 3.14–3.25 (m, 2H, piperidine-CHAr and 
Hax of s-anti amide piperidine NCH2), 3.76 (s) and 3.75 (s, 3H, 
OMe), 3.79 (s, 3H, OMe), 4.09–4.16 (m, 1H, Heq of s-anti amide 
piperidine NCH2), 4.65–4.70 (m, 1H, a-CH), 4.74–4.76 (m, 1H, Heq 
of s-syn amide piperidine NCH2), 4.87–4.90 (m, 1H, a-CH), 6.71–
6.73 (m, 2H), 6.78–6.80 (m, 1H), 6.87 (d, J = 9.0 Hz) and 6.89 (d, J 
= 9.0 Hz, 1H, NH), 6.93 (d, 1H, J = 1.8 Hz, isoxazole-CH), 7.08–
7.11 (m, 1H, NH), 8.34 (s, 1H, isoxazole-CH); 13C NMR (100 MHz, 
CDCl3): 11.3/11.5 (Ile-d-CH3), 15.8/16.1 (Ile-g-CH3), 
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23.9(9)/24.0(4) (Ile-g-CH2), 26.0, 26.1, 26.3 31.4(5)/31.5(3), 32.2, 
32.5/32.6, 33.6, 34.0/34.1, 35.5/35.9, 38.1, 40.2, 43.3/43.4, 
46.7/47.1, 51.3(5)/51.4(2), 53.0/53.1, 55.7, 55.8/55.9, 106.7, 
110.6/111.0, 111.3, 113.4/113.8, 127.3, 134.1, 151.0, 153.7, 155.4, 
162.4, 169.8/169.9, 171.1/171.2. 
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tR = 12.8 min (Method II); HRMS: calc. for C31H42F3N4O4+ [MH]+ 
591.3153, found 591.3156; 1H NMR (600 MHz, CDCl3) (two 
rotamers in a ratio of 59:41) δ 0.86–1.07 (m, 8H), 1.08–1.59 (m, 
7H), 1.61–2.01 (m, 9H), 2.70–2.78 (m, 1H, Hax of s-syn amide 
piperidine NCH2), 3.19–3.28 (m, 2H, piperidine-CHAr and Hax of s-
anti amide piperidine NCH2), 4.16–4.23 (m, 1H, Heq of s-anti amide 
piperidine NCH2), 4.66–4.74 (m, 1H, Cha-a-CH), 4.81 (d, J = 13.0 
Hz, 1H, Heq of s-syn amide piperidine NCH2), 4.89–4.94 (m, 1H, Ile-
a-CH), 6.83 (d, J = 8.4 Hz, minor) and 6.92 (d, J = 9.0 Hz, major, 
1H), 6.95 (d, 1H, J = 1.8 Hz, isoxazole-CH), 7.08–7.13 (m, 1H), 
7.31–7.42 (m, 2H), 7.51–7.56 (m, 1H), 7.64–7.67 (m, 1H), 8.36 (d, 
1H, J = 1.8 Hz, isoxazole-CH).  
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tR = 12.0 min (Method II); HRMS: calc. for C32H41F6N4O5+ [MH]+ 
675.2976, found 675.2976; 1H NMR (600 MHz, CDCl3) (two 
rotamers in a ratio of 2:1), δ 0.86–1.03 (m, 8H), 1.08–2.30 (m, 
19H), 3.17–3.22 (m, 1H, Hax of s-syn amide piperidine NCH2), 3.66–
3.71 (m, 1H, Hax of s-anti amide piperidine NCH2), 3.98 (d, J = 13.2 
Hz, minor) and 4.04 (d, J = 13.2 Hz, major, 1H, Heq of s-anti amide 
piperidine NCH2), 4.61–4.68 (m, 2H, Cha-a-CH and Heq of s-syn 
amide piperidine NCH2), 4.87–4.91 (m, 1H, Ile-a-CH), 6.78 (d, J = 
9.0 Hz, minor) and 6.88 (d, J = 8.4 Hz, major, 1H, NH), 6.92 (d, J = 
1.8 Hz, major) and  6.94 (d, J = 1.8 Hz, minor, 1H, isoxazole-CH), 
7.03 (d, J = 7.8 Hz, major) and 7.07 (d, J = 8.4 Hz, minor, 1H, NH), 
7.71 (d, 1H, J = 9.0 Hz), 7.78–7.82 (m, 1H), 8.05 (br s, 1H), 8.35 (d, 
1H, J = 1.8 Hz, isoxazole-CH).  
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tR = 8.3 min (Method II); HRMS: calc. for C32H46N5O5+ [MH]+ 
580.3493, found 580.3493; 1H NMR (600 MHz, DMSO-d6) (two 
rotamers in a ratio of 62:38), δ 0.79–0.93 (m, 8H), 1.01–1.33 (m, 
5H), 1.46–1.85 (m, 11H), 1.88 (s, minor) and 1.91 (s, major, 3H, 
Ac), 2.38–2.45 (m, 2H), 2.83–2.90 (m, 1H, Hax of s-syn amide 
piperidine NCH2), 3.24–3.32 (m, 1H, Hax of s-anti amide piperidine 
NCH2), 3.97–4.03 (m, 1H, Heq of s-anti amide piperidine NCH2), 
4.27 (d, J = 13.2 Hz, minor) and 4.34 (d, J = 12.6 H, major, 1H, Heq 
of s-syn amide piperidine NCH2), 4.52–4.58 (m, 2H, 2 ´ a-CH), 
7.13 (d, J = 1.8 Hz, major), and 7.16 (d, J = 1.8 Hz, minor, 1H, 
isoxazole-CH), 7.18–7.22 (m, 1H), 7.26–7.34 (m, 4H), 8.06 (s, 
major) and 8.07 (s, minor, 1H, AcNH), 8.16 (d, J = 9.0 Hz, minor) 
and 8.28 (d, J = 9.0 Hz, major, 1H, NH), 8.73 (d, J = 1.8 Hz, major) 
and 8.75 (d, J = 1.8 Hz, minor, 1H, isoxazole-CH), 8.91 (d, J = 8.4 
Hz, minor) and 8.92 (d,  major, 1H, J = 8.4 Hz, NH); 13C NMR (150 
MHz, CDCl3): 11.5/11.6 (Ile-d-CH3), 16.0/16.1 (Ile-g-CH3), 
23.9(6)/24.0(3) (Ac), 24.3(9)/24.4(3) (Ile-g-CH2), 26.0, 
26.1(6)/26.2(1)/26.2(8), 26.5, 32.2/32.3, 33.6/33.7, 34.1/34.2, 35.4, 
36.1/36.3, 36.5/36.7, 38.2(9)/38.3(4), 39.3(3)/39.4(1), 42.0/42.2, 
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51.3/51.4 (a-CH), 52.6/52.7 (a-CH), 56.5/56.7 (C), 106.6/106.7 
(isoxazole-4-CH), 125.3/125.5 (CH), 126.7/126.8 (CH), 128.5/129.6 
(CH), 147.1/147.2 (C), 152.1(8)/152.2(3) (isoxazole-3-CH), 155.8 
(C), 162.8 (C), 163.2 (C), 169.6/169.8 (C), 171.6/171.7 (C). 
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tR = 12.2 min (Method II); HRMS: calc. for C31H45N4O4+ [MH]+ 
537.3435, found 537.3449; 1H NMR (400 MHz, DMSO-d6) (two 
rotamers in a ratio of 58:42), δ 0.76–1.40 (m, 15H), 1.40–1.82 (m, 
12H), 2.32–2.50 (m, 1H, Hax of s-syn amide piperidine NCH2), 2.50 
(CH2Ph, overlapped with the solvent peak), 2.89–2.98 (m, 1H, Hax of 
s-anti amide piperidine NCH2), 4.02 (d, 1H, J = 12.8 Hz, Heq of s-
anti amide piperidine NCH2), 4.31–4.38 (m, 1H, Heq of s-syn amide 
piperidine NCH2), 4.50–4.60 (m, 2H, 2 ´ a-CH), 7.12–7.30 (m, 6H), 
8.04 (d, J = 8.8 Hz, minor) and 8.16 (d, J = 9.2 Hz, major, 1H, NH) 
8.74 (s, minor) and 8.76 (s, major, 1H, isoxazole-CH), 8.89–8.95 
(m, 1H, NH).  
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tR = 14.3 min (Method II); HRMS: calc. for C36H47N4O4+ [MH]+ 
599.3592, found 599.3597; 1H NMR (400 MHz, CDCl3) (two 
rotamers in a ratio of 56:44), δ 0.79–1.54 (m, 14H), 1.54–1.86 (m, 
12H), 2.45–2.51 (m, 1H, Hax of s-syn amide piperidine NCH2), 2.91–
2.99 (m, 2H, piperidine-CHAr and Hax of s-anti amide piperidine 
NCH2), 4.05 (d, 1H, J = 13.2 Hz, Heq of s-anti amide piperidine 
NCH2), 4.65–4.72 (m, 2H, a-CH and Heq of s-syn amide piperidine 
NCH2), 4.82–4.90 (m, 1H, a-CH), 6.86 (d, J = 9.2 Hz) and 6.92 (d, J 
= 9.2 Hz, 1H, NH), 6.93 (d, J = 1.8 Hz, minor) and 6.94 (d, J = 1.8 
Hz, major, 1H, isoxazole-CH), 7.11 (d, J = 8.8 Hz) and 7.16 (d, J = 
8.4 Hz, 1H, NH), 7.19–7.45 (m, 9H), 8.33 (d, J = 1.8 Hz, major) and 
8.34 (d, J = 1.8 Hz, major, 1H, isoxazole-CH); 13C NMR (100 MHz, 
CDCl3): 11.4/11.7 (Ile-d-CH3), 15.8/16.3 (Ile-g-CH3), 24.2 (Ile-g-
CH2), 26.1(3)/26.2(0)/26.2(5)/26.3(3), 26.4(3)/26.4(4), 32.7/32.8, 
33.2, 33.8/34.1/34.3, 38.2(6), 38.3(4)/38.4(8), 40.4/40.5, 
43.1(8)/43.2(3), 46.7/47.1, 51.4/51.5/51.6, 53.0(6)/53.1(1)/53.1(6), 
106.9, 126.2(6)/126.2(8), 127.1(6)/127.2(4), 128.0, 128.4, 129.3, 
130.4/139.6, 141.6, 141.7/141.8, 142.1(9)/141.2(3), 151.2, 155.5, 
162.6, 170.0, 171.3. 
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tR = 14.3 min (Method II); HRMS: calc. for C36H47N4O4+ [MH]+ 
599.3592, found 599.3590; 1H NMR (400 MHz, CDCl3) (two 
rotamers in a ratio of 1:1), δ 0.84–2.09 (m, 26H), 2.72–2.89 (m, 2H, 
piperidine-CHAr and Hax of s-syn amide piperidine NCH2), 3.20–
3.26 (m, 1H, Hax of s-anti amide piperidine NCH2), 4.18–4.25 (m, 
1H, Heq of s-anti amide piperidine NCH2), 4.66–4.72 (m, 1H, a-CH), 
4.79 (d, 1H, J = 12.8 Hz, Heq of s-syn amide piperidine NCH2), 
4.88–4.96 (m, 1H, a-CH), 6.92 (d, J = 2.0 Hz) and 6.94 (d, J = 2.0 
Hz, 1H, isoxazole-CH), 6.99–7.04 (m, 1H), 7.14–7.60 (m, 10H), 
8.33 (d, J = 2.0 Hz) and 8.34 (d, J = 2.0 Hz, 1H, isoxazole-CH); 13C 
NMR (100 MHz, CDCl3): 11.3/11.5 (Ile-d-CH3), 15.7/16.1 (Ile-g-
CH3), 24.0/24.1 (Ile-g-CH2), 26.0/26.1/26.2, 32.5/32.6, 32.9/33.0, 
33.6, 33.8, 34.0(5)/34.1(0), 38.1, 40.2, 42.5/42.8, 43.2, 46.6/47.1, 
51.3/51.4/51.5, 53.0/53.1/53.2, 106.8, 125.5/125.6/125.7, 
127.2/127.3, 128.7/129.1, 141.1, 141.6(6)/141.7(0), 145.1/145.2, 
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151.0, 155.4, 162.4, 170.1, 171.3/171.4. 
75 
 
tR = 13.6 min (Method II); HRMS: calc. for C36H47N4O4+ [MH]+ 
599.3592, found 599.3594; 1H NMR (400 MHz, CDCl3) (two 
rotamers in a ratio of 1:1), δ 0.85–2.07 (m, 26H), 2.70–2.88 (m, 2H, 
piperidine-CHAr and Hax of s-syn amide piperidine NCH2), 3.18–
3.27 (m, 1H, Hax of s-anti amide piperidine NCH2), 4.14–4.20 (m, 
1H, Heq of s-anti amide piperidine NCH2), 4.65–4.72 (m, 1H, a-CH), 
4.79 (d, 1H, J = 11.6 Hz, Heq of s-syn amide piperidine NCH2), 
4.88–4.94 (m, 1H, a-CH), 6.75 (app t, 1H, J = 9.6 Hz, NH), 6.93–
6.94 (m, 1H, isoxazole-CH), 7.07 (app t, 1H, J = 9.6 Hz, NH), 7.26–
7.58 (m, 9H), 8.33–8.34 (m, 1H, isoxazole-CH).  
76 
 
tR = 13.2 min (Method II); HRMS: calc. for C36H47N4O5+ [MH]+ 
615.3541, found 615.3546; 1H NMR (400 MHz, DMSO-d6) (two 
rotamers in a ratio of 64:36), δ 0.88–2.00 (m, 26H), 2.69–2.78 (m, 
1H), 2.87–2.94 (m, 1H), 3.16–3.27 (m, 1H), 4.28 (d, 1H, J = 12.8 
Hz, Heq of s-anti amide piperidine NCH2), 4.62–4.75 (m, 3H, 2 ´ a-
CH and Heq of s-syn amide piperidine NCH2), 7.00–7.58 (m, 10H), 
8.21 (d, J = 9.6 Hz, minor) and 8.34 (d, J = 9.6 Hz, major, NH), 8.83 
(d, J = 1.8 Hz, major) and 8.85 (d, J = 1.8 Hz, minor, 1H, isoxazole-
CH), 9.02 (d, 1H, J = 8.4 Hz, NH). 
 
Calculation of Volume: Chemical structures of different R1-R4 substituents in ligands reported 
here were drawn in ChemDraw 13.0.  “Ligand Preparation” module within Maestro, version 9.5 
(Schrödinger, LLC, New York, NY, 2013) was used to convert 2D structures to 3D co-ordinates 
and saved as mol2 files. Gaussian 09 software was used for calculation of molar volume 
(cm3/mole) of the R groups. Before quantum chemical calculations, a molecular mechanic 
minimization was performed with the UFF force field available in Gaussian 09. Further 
calculations were performed at the level of B3LYP/6-311+g(d,p) basis set in vacuum. 
Intracellular calcium release assay. Adherent colorectal adenocarcinoma cells (HT29) were 
plated at ~2 x 104 cells/well in a 96-well cleared-bottomed black-walled assay plate (Corning) 
with equal amounts of medium added and incubated overnight at 37oC. Before assay, the 
medium was removed and cells were incubated with dye-loading buffer (12 mL HBSS buffer, 2 
mM Fluo-3 AM, 25 μL Pluronic acid F-127 and 1% v/v fetal calf serum) for an hour at 37oC. 
After an hour, cells were washed once with assay buffer (HBSS supplemented with 2.5 mM 
probenecid and 20 mM HEPES, pH 7.4). All final compounds were dissolved in DMSO to make 
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a 10 mM stock solution for intracellular calcium release assays on HT29 cells. The stock sample 
was then diluted with HBSS buffer to give the desired concentrations for the calcium efflux 
assay. The concentration of DMSO in the assay was no more than 2%. For the antagonist assay, 
the cells were pre-incubated with desired concentrations of the synthesized compounds for 30 
min before the addition of agonist (2f-LIGRLO-NH2, 1 μM). Fluostar Optima (BMG 
Labtechnologies) or FLIPR (Molecular Devices) was used to monitor the intracellular release of 
Ca2+ via fluorescence measurement for at least 60 s (excitation 495 nm, emission 520 nm). The 
agonist assay was conducted in a similar manner, except that the intracellular Ca2+ release was 
monitored immediately after the injection of the desired concentration of the synthesized 
compounds. To assess potential antagonist in more detail, concentration dependent inhibition 
assay was conducted. A range of concentrations of the compound was pre-incubated with the 
cells. Duplicate measurements were made for each data point, mean ± SEM are reported from 
multiple experiments as indicated. Net changes in fluorescence were calculated as a percentage 
relative to the maximum response given by the test compound. Changes in fluorescence (% 
response) were plotted against logarithmic compound concentrations. The half maximal 
inhibitory concentration (IC50) values were derived from the concentration response curve using 
a nonlinear regression curve in Graphpad Prism v5. 
Antagonist surmountability. Cells were prepared as for the calcium mobilization assay. After 
1 h incubation with dye loading buffer, cells were incubated with different concentrations of 
antagonist for 15 min before the addition of agonist (2f-LIGRLO-NH2). The plate was read using 
FLIPR (Molecular Devices) and examined for concentration-dependent effects on the activity of 
agonist in the presence of different concentrations of antagonist. 
PAR2 transfected CHO cells. Human PAR2 cDNA was cloned into pcDNA5/FRT vector 
(Invitrogen) at BamHI site and incorporated into Flp-In-CHO cells (Invitrogen) using 
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Lipofectamine 2000 (Invitrogen) according to manufacturer’s instruction. Stable PAR2-CHO 
cells were then selected using 600 µg/mL of Hygromycin B.  
cAMP accumulation. LANCE Ultra cAMP assay was performed in accordance with 
manufacturer’s instructions (PerkinElmer). In brief, cells were dissociated from flasks by 
Versene (Invitrogen) on the day of experiment. Cells (5 μL, 4 ´ 105 cells/mL) were transferred to 
a 384-well proxiplate (PerkinElmer) and incubated with various concentrations of 65 for 20 min 
at room temperature. Forskolin (120 nM) was then added into each well and incubated for a 
further 10 min at room temperature. Finally, Eu-cAMP tracer (5 μL) and ULight™-anti-cAMP 
(5 μL) were added to each well and incubated for 1 h at room temperature. The plate was read 
using a Pherastar FS fluorimeter (BMG, Germany).  
ERK1/2 phosphorylation. SureFire phospho-ERK1/2 assay was performed in accordance 
with manufacturer’s instructions (PerkinElmer). In brief, cells were seeded overnight in 96-well 
tissue culture plate (~5 ´ 104 cells per well). On the day of experiment, cells were treated with 
various concentrations of compounds dissolved in serum-free medium and incubated for 10 min 
at 37 °C. Supernatant was removed and cells were lysed with cell lysis buffer provided by the 
kit. Cell lysate (4 μL) was transferred to a 384-well proxiplate (PerkinElmer) and incubated with 
reaction mixture (7 μL) for 2 h at room temperature before plate reading. 
Stability studies on PAR2 agonists and antagonists in rat plasma and liver homogenate. 
Blood and whole liver samples were collected from non-drug dosed male and female Wistar rats 
(aged 8–9 weeks, 200–250 g and 250–300 g respectively). Blood samples were centrifuged at 8k 
rpm for 5 min.  Plasma samples were pooled and stored at –80 °C for later use.  The rat livers 
were homogenized, diluted with three volumes of PBS and cloth filtered.  The filtrate was used 
directly for stability studies. Each compound was dissolved in DMSO to make 5 mM stock 
solution. 10 µL of the stock was diluted with either rat plasma or liver homogenate (490 µL) to 
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make up a starting concentration of 10 µM (performed in triplicate).  The mixtures were 
vortexed and incubated at 37 ºC.  At each time point of 0, 30, 60 and 180 minutes, 100 µL of the 
mixture was taken and diluted with 300 µL of acetonitrile.  The mixture was vortexed and 
centrifuged. 350 µL of the liquid was transferred into a microfuge tube and concentrated using a 
rotational vacuum concentrator (Christ Beta-RVC, supplied by Quantum Scientific). 100 µL of 
acetonitrile–water (9:1, v/v) was added to the residue, vortexed and immediately analyzed by 
LCMS/MS. Data from these experiments are expressed as percent of peak area recorded from 
the LCMS/MS trace at time zero (t0). 
In vivo efficacy using the PAR2-agonist induced paw oedema . The methods used are based 
on those previously described.1-3 Male Wistar rats (n = 3–5 per group) were used. Briefly, rats 
were given 10 mg/kg of a compound orally (p.o. via gavage in olive oil, approx. 500 µL, weight 
adjusted). Control animals received only olive oil or saline (500 µL p.o.). After a relevant 
absorption period (2 h for oral), the PAR2 agonist 2-f-LIGRLO-NH2 (350 µg/paw in saline, 100 
µL) was injected into the plantar surface (i.pl.) of the right paw pad using a 30 G needle. The left 
paw acted as a control, receiving saline only. Paw thickness and width were measured at given 
time points (30 min, 60 min, 2 h, 3 h) thereafter using digital callipers (World Precision 
Instruments, USA) and swelling was calculated in area (mm2; thickness multiplied by width). 
Data is expressed as a percentage change from baseline of each individual paw, mean ± SEM. 
Statistical tests performed were repeated measures ANOVA with Bonferroni planned 
comparisons, using GraphPad Prism software (v5.0c). 
Human tubule epithelial cells (HTEC) isolation and culture. Segments of macroscopically 
and histologically normal renal cortex (5–10 g) were obtained aseptically from the non-
cancerous pole of adult human kidneys removed surgically because of small renal cancers. 
Patients were otherwise healthy. Informed consent was obtained prior to each operative 
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procedure and the use of human renal tissue for primary culture was reviewed and approved by 
the Princess Alexandra Hospital Research Ethics Committee. The method for isolation and 
primary culture of human tubule epithelial cells (HTEC) is described in detail from literature.4,5 
Briefly the cortical tissue was minced finely, washed several times and agitated for 20 minutes at 
37 °C in a Hank Balanced Salt Solution (HBSS) with Ca2+ & Mg2+ containing collagenase type II 
(1mg/ml). Cold HBSS was added and the solution passed through a 297 µm sieve (50 Mesh, 
Sigma). After washing three times the tubular fragments were resuspended in 45% percoll – 
KHB and centrifuged at 25000 xg. A high density band previously shown to be tubule fragments 
was removed and cultured in a serum free, hormonally defined media (DMEM/F12 containing 
10 ng/ml epidermal growth factor, 5 µg/ml insulin, 5 µg/ml transferrin, 50nM hydrocortisone, 50 
µM prostaglandin E1, 50 nM selenium and 5 pM triiodothyronine.  
Treatment of human tubule epithelial cells (HTEC). All experiments were performed on 
confluent passage 2 HTEC, (in 48 well plates), made quiescent by two washes followed by 
incubation for 24 hours in serum and growth factor free DMEM/F12 media. Compounds diluted 
in DMEM/F12 were added to the cells at the concentrations shown. Antagonists were added 30 
mins prior to agonist addition. Conditioned medium was collected from the cells at 24h and 
stored at –80°C until assayed. 
Enzyme-linked immunosorbent assay. Cytokines (IL-6 & TNF-α) were examined either 
using BD Pharmingen ELISA set or R&D Duoset according to the manufacturer’s protocols. 
Briefly, plate was coated with capturing antibody at 4°C overnight before being blocked with 
10% serum or 1% BSA for 1 h at room temperature. Samples and standards were diluted in 
blocking buffer, added to each well and incubate for 2 h at room temperature. The HRP 
conjugated detection antibody was added and incubated for a further 1–2 h at room temperature. 
K-blue substrate (Elisa Systems, Brisbane Australia) was allowed to develop for 30 min in the 
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dark and stopped by 2 M sulfuric acid. A BMG Polarstar spectrofluorimeter was used to measure 
the absorbance at 450 nM. 
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